

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effects of Pulsed Low Frequency Magnetic Field Therapy on Pain Intensity in Patients with Musculoskeletal Chronic Low Back Pain: A Randomized Double Blind Placebo Controlled Trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024650
Article Type:	Protocol
Date Submitted by the Author:	06-Jun-2018
Complete List of Authors:	Abdulla, Fuad; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Alsaadi, Saad; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Sadat-Ali, MIR; Imam Abdulrahman Bin Faisal University, Department of Orthopedic Surgery Alkhamis, Fahd; Imam Abdulrahman Bin Faisal University, Department of Neurology Alkawaja, Hani; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Lo, Serigne; Imam Abdulrahman Bin Faisal University, Institute of Research and Medical Consultation; Melanoma Institute Australia
Keywords:	Back pain < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT, REHABILITATION MEDICINE, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2 **Effects of Pulsed Low Frequency Magnetic Field Therapy on Pain Intensity in Patients**  
3  
4 **with Musculoskeletal Chronic Low Back Pain: A Randomized Double Blind Placebo**  
5  
6 **Controlled Trial.**  
7

8  
9 Fuad A. Abdulla<sup>1</sup>, Saad AlSaadi<sup>1</sup>, MIR Sadat-Ali<sup>2</sup>, Fahd AlKhamis<sup>3</sup>, Hani Alkhawaja<sup>1</sup> and Serigne Lo<sup>4,5</sup>.  
10

- 11 1. Department of Physical Therapy, Imam Abdulrahman Bin Faisal University, Dammam, KSA
- 12 2. Department of Orthopedic Surgery, Imam Abdulrahman Bin Faisal University, Dammam, KSA
- 13 3. Department of Neurology, Imam Abdulrahman Bin Faisal University, Dammam, KSA
- 14 4. Institute for Research and Medical Consultations (IRMC), University of Dammam, Dammam,  
15 KSA
- 16 5. Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26

27 Correspondence to Prof. Fuad A Abdulla:

28  
29 P.O. Box 2435 Dammam 31451, KSA

30  
31 E-mail: faabdullah@iau.edu.sa

32  
33 Tel: 00966133331308  
34  
35  
36

37 Word count: 3642,

38  
39 57 references,

40  
41 One Table,

42  
43 One Figure,

44  
45 One Appendix  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** The aim of the present study is to investigate the effectiveness of pulsed low frequency magnetic field (PLFMF) on the management of chronic low back pain (CLBP).

**Methods and Analysis:** A randomized double blinded controlled clinical trial will be conducted, involving 200 patients with CLBP. Participants will be randomized in a 1:1 ratio to receive either active PLFMF (experimental arm) or sham treatment (control arm) using a permuted-block design which will be stratified according to three subtypes of musculoskeletal CLBP (nociceptive, peripheral neuropathic or central sensitization). Intervention consists of 3 sessions/week for 6 weeks. The primary outcome is the percentage change in Numeric Rating Scale (NRS) pain at week-24 after treatment completion with respect to baseline. Secondary outcomes includes percentage NRS pain during treatment and early after treatment completion, short form 36 quality of life, Roland and Morris Disability Questionnaire; Depression Anxiety Stress Scale 21, Patient Specific Functional Scale, Global perceived effect of condition change, Pittsburgh Sleep Quality Index and Modified Fatigue Impact scale. Measures will be taken at baseline, 3 and 6 weeks during intervention and 6, 12 and 24 weeks after completing the intervention. Adverse events between arms will be evaluated. Data will be analyzed on an intention-to-treat basis.

**Conclusion:** This randomized trial is powered to assess the effectiveness of PLFMF on the management of musculoskeletal CLBP.

**Ethics and dissemination:** The study is funded by Imam Abdulrahman Bin Faisal University (IAU). It has been approved by the IRB of IAU (IRB- 2017-03-129). The study will be conducted at King Fahd Hospital of the University and will be monitored by the Hospital monitoring office for research and research ethics. The trial is scheduled to begin September

1 2018. Results obtained will be presented in international conferences and will be published in  
2  
3  
4 peer-reviewed journals.  
5

6  
7 **Trial registration number** ACTRN12618000921280, prospectively.  
8  
9

10 **Key words:** Low back pain, Pulsed low frequency magnetic field, Randomized double blinded  
11 controlled clinical trial, Efficacy, Safety  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Strengths and limitations of this study

- The present study is a well-designed trial to investigate the long-term efficacy and safety of PLFMF on the management of musculoskeletal chronic low back pain.
- Subgroup analysis investigating efficacy of PLFMF on various subtypes of pain based on pain mechanism will be performed. This may help to explain controversial results reported by previous clinical trials.
- Outcome measures include various aspects of low back pain problems (pain intensity as well as disabilities, functional limitations, sleep quality and quality of life).
- All outcome measures used in the present trial are self-report which may potentiate pain and other measured outcome.

## INTRODUCTION

Chronic low back pain (CLBP) is pain or discomfort localized in the lumbosacral region, with or without leg pain (sciatica) that persists for more than 3 months.<sup>1</sup> Eight out of every 10 adults will experience low back pain (LBP) at least once in their life with more than 60% of such cases have a recurrent LBP.<sup>2</sup> The causes of LBP are many, they can range from simple spasm or mechanical causes to more serious causes such as herniated disc and different types of cancer.<sup>3</sup> Symptoms of LBP may vary from one patient to another. In many patients the symptoms may go beyond pain to lead to severe consequences such as sleep disturbances, psychological and social problems which may affect the quality of life.<sup>4</sup> CLBP accounts for about 15% of all cases of LBP, however, it has been reported to be the world-leading source of disability.<sup>5</sup> In addition, CLBP is often associated with socioeconomic burden and psychological distress.<sup>6</sup> For example, the treatment cost for low back pain in the US is estimated to be more than \$90 billion per year<sup>7</sup> and \$17 billion per year in the UK.<sup>8</sup>

LBP can be classified based on several criteria. It has been classified to acute and chronic based on how long the pain has persisted. It can also be classified into inflammatory and neuropathic based on the underlying mechanism.<sup>9</sup> The main issue is how to differentiate the various subtypes clinically. In many occasions differentiating the various phenotypes clinically is difficult. Smart et al.<sup>10-12</sup> proposed a mechanism based classification to differentiate between different types of musculoskeletal LBP (central sensitization, peripheral neuropathic and nociceptive).

Most of mechanical low back pain respond to rest and various physical modalities. Different conservative and surgical interventions have been used to manage CLBP; however, the optimal therapy is still debatable.<sup>13</sup> Many physical therapy interventions were tried in the management of

1 CLBP such as soft tissue mobilization and neurodynamic techniques,<sup>14-15</sup> massage therapy,<sup>16</sup>  
2 ultrasound, laser therapy and shock wave therapy,<sup>17</sup> exercises,<sup>18</sup> Pilates practice<sup>19</sup> and  
3  
4  
5  
6 acupuncture.<sup>20</sup> While some of the rehabilitation interventions were effective on the short term,  
7  
8 none of such interventions produced long term effectiveness in the management of CLBP.  
9

10  
11  
12  
13 Many pharmacological interventions have been used to manage CLBP. For example non-steroid  
14 anti-inflammatory drugs and trammel were mildly to moderately effective in reducing pain  
15 without much effects on function.<sup>16</sup> Similarly, opioids, benzodiazepines and duloxetine effects  
16 on reducing CLBP were small without inducing any improvement in functions.<sup>21</sup> Other drugs  
17 were used such as Tricyclic antidepressants, gabapentin, however, their efficacy were not  
18 established.<sup>22</sup> Since the CLBP persist for long term, pharmacological interventions are not a  
19 suitable solution due to many reasons. Such reasons include toxicity due to long term use, side  
20 and adverse effects in addition to problems with tolerance and addiction.<sup>23</sup> Surgical procedures  
21 have been used in some cases of CLBP with mixed outcome,<sup>24</sup> however, many patients are  
22 reluctant to go through surgery. Add to that the high cost of the surgery to the health care system.  
23  
24 Furthermore, the number of what is called “failed back surgery syndrome” are in the rise.<sup>25</sup>  
25  
26 Since the conservative approaches currently used to manage CLBP do not seem to be effective  
27 on the long term, new approaches are needed to be developed. The new approaches should be  
28 safe, noninvasive and cost effective.  
29  
30

31  
32 Several lines of evidence indicate that pulsed low frequency magnetic field (PLFMF) may be an  
33 attractive option for the management of CLBP. Magnetic field blocked the sensory neuron action  
34 potential in cultured neurons,<sup>26</sup> however, it enhanced neuronal growth in the presence of growth  
35 factor.<sup>27</sup> In rats, magnetic field suppressed the formation of edema.<sup>28</sup> Weintraub et al.<sup>29</sup> showed  
36 that magnetic field has a pronounced anti-nociceptive effect. Robertson et al.<sup>30</sup> showed that  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 PLFMF affected pain and thermal signals in normal volunteers. Selvam et al.<sup>31</sup> reported that  
2  
3 PLFMF restored the calcium ATPase activity of the plasma membrane and produced anti-  
4  
5 inflammatory effects. PLFMF also inhibited pain processing in a dose dependent manner.<sup>32</sup>  
6  
7 Clinically PLFMF has been used for the treatment of different types of pain. Such as planter  
8  
9 fasciitis,<sup>33</sup> lumbar radicular pain,<sup>34</sup> postoperative pain,<sup>35</sup> peripheral neuropathy<sup>29</sup> and  
10  
11 osteoarthritis.<sup>36</sup> Recently we concluded a study which showed that PLFMF was effective in  
12  
13 reducing pain, improving sleep and quality of life in patients with carpal tunnel syndrome.<sup>37</sup>  
14  
15 In the case of CLBP few studies were done and produced conflicting results. While Kramer et  
16  
17 al.,<sup>13</sup> Oke and Umebese,<sup>38</sup> and Harden et al.<sup>39</sup> reported that PLFMF was not superior to sham  
18  
19 treatment in patients with CLBP other studies reported that PLFMF significantly reduced pain  
20  
21 intensity in patients with CLBP.<sup>40-42</sup> Most of the six studies which tested the effects of PLFMF  
22  
23 on CLBP suffered from methodological problems and flaws. Such problems included failure to  
24  
25 perform intention to treat as well as lack of proper blindness of patients and researchers. All  
26  
27 these studies failed to classify the CLBP into different subgroups since CLBP is heterogeneous.  
28  
29 Two of the studies reporting positive findings failed to compare PLFMF with other therapeutic  
30  
31 modality.<sup>41-42</sup> All the mentioned studies used small number sample sizes (16 – 40 patients). Some  
32  
33 of these studies did not do any follow-up after the conclusion of the interventions or a follow-up  
34  
35 for short period.<sup>43</sup> Finally the six studies used different machine producing different magnetic  
36  
37 field intensity and frequency and different treatment protocols. Similarly, various studies  
38  
39 reported controversial results regarding the effects of PLFMF on level of disability and quality of  
40  
41 life in patients with CLBP. Some studies reported that PLFMF improved level of disability  
42  
43 and/or quality of life<sup>40-41,44</sup> while other studies reported no effects for PLFMF on disability  
44  
45 and/or quality of life.<sup>13,42,45</sup> Two systematic reviews investigated the effects of PLFMF on CLBP.  
46  
47 Andrade et al.<sup>43</sup> concluded that PLFMF treatment is superior to placebo treatment. However,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Hug and Roosli<sup>46</sup> concluded that available evidence is not sufficient to recommend the use of  
2 PLFMF clinically. Both reviews recommended better controlled randomized studies are needed  
3  
4 to clarify the effects of PLFMF on CLBP.  
5  
6

7  
8 PLFMF is known to be safe, non-invasive, low cost, easy to administer and has no known side  
9  
10 effects in the management of patients with CLBP.<sup>46</sup> Improving the condition of patients with  
11  
12 CLBP will spare the patient going through several rounds of pharmacological and non-  
13  
14 pharmacological treatment as well as invasive procedures like surgery with the ultimate goal to  
15  
16 improve the patient quality of life.  
17  
18  
19  
20  
21  
22

## 23 **OBJECTIVES**

24  
25  
26 The primary objective of this randomized controlled trial is to evaluate the long-term efficacy  
27  
28 and safety of PLFMF on the management of CLBP in increasing the percentage change in  
29  
30 Numeric Rating Scale (NRS) pain at week-24 with respect to baseline score. The percentage  
31  
32 reduction in Numeric Rating Scale (NRS) pain at week-24 will also be evaluated according to  
33  
34 various musculoskeletal CLBP subtypes based on pain mechanism (nociceptive versus peripheral  
35  
36 neuropathic versus central sensitization).  
37  
38

39  
40 The secondary objectives are to evaluate the effects of PLFMF on: 1) pain intensity during  
41  
42 treatment and early after treatment completion, 2) level of disability, 3) functional levels, 4)  
43  
44 sleep quality, 5) quality of life and 6) fatigue in patients with CLBP. The study will also  
45  
46 investigate the long term side effects of PLFMF.  
47  
48

49 This study will also include subgroups exploratory objectives to clarify the role of PLFMF in the  
50  
51 management of patients diagnosed with different subtypes of musculoskeletal CLBP. To the best  
52  
53 of our knowledge, this trial is the first randomized clinical trial to explore simultaneously the role  
54  
55  
56  
57

1 of PLFMF in the management of peripheral neuropathic, nociceptive and central sensitization  
2  
3  
4 musculoskeletal LBP patients together.  
5  
6  
7  
8  
9

## 10 **METHODS and analysis**

11  
12  
13 Study design This is a two-arm randomized, double blind, placebo controlled clinical trial. The  
14  
15 study will be coordinated at the King Fahd Hospital. All participants will be recruited from the  
16  
17 Hospital (patients referred to the department, additionally flyers will be distributed inviting  
18  
19 people to participate). This study is funded through the Imam Abdulrahman Bin Faisal  
20  
21 University project grant (number 2017-308-CAMS). Ethical approval has been obtained from the  
22  
23 IRB of the Imam Abdulrahman Bin Faisal University (IRB□ 2017□03-129). This study is  
24  
25 prospectively registered with the Australian New Zealand clinical Trials Registry (Registration  
26  
27 Number ACTRN12618000921280). Table 1 Trial Registration Data Set. This trial protocol has  
28  
29 been prepared according the SPIRIT checklist statement.<sup>47</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

Insert Table 1 about here

## 41 **Sample Size and power calculation**

42  
43  
44 A total sample size of 200 (100 in each arm) will achieve 90% power to detect a mean difference  
45  
46 of percentage reduction in Numerical rating scale (NRS) pain of 10% between the two treated  
47  
48 arms at week-24. The mean percentage reduction in NRS pain is assumed to be 15% in the  
49  
50 control arm (patient treated with SHAM program) and 25% in patients who receive PLFMF  
51  
52 therapy. A 25 standard deviation is considered along with a two-sided significance level (alpha)  
53  
54 of 5% using a two-sample equal-variance t-test. The sample size allows for 15 percent of patients  
55  
56  
57  
58  
59  
60

1  
2 lost to follow-up at week 24.  
3  
4

5 Mechanism-based classification will be used to classify patients into different phenotypes of  
6 musculoskeletal CLBP. This method discriminative validity was established.<sup>10-12</sup> All patients will  
7 be analyzed collectively. Subgroup analysis will be performed to assess the effect of PLFMF on  
8 subtypes of pain.  
9  
10  
11  
12

### 13 14 15 **Statistical Analysis** 16

17  
18 All randomized patients will be analyzed on the intent-to-treat basis. Safety analyses will be  
19 performed for all patients who received at least one treatment session. Data will be coded and  
20 entered into SPSS program for analysis. Baseline characteristics will be presented by treatment  
21 group. Binary and categorical variables will be summarized by frequencies and percentages.  
22  
23  
24

25 Percentages will be calculated according to the number of patients for whom data are available.  
26  
27

28 Where values are missing, the denominator, which will be less than the number of patients  
29 assigned to the treatment group will be reported either in the body or a footnote of the summary  
30 table. Continuous variables will be summarized by mean and standard deviation as well as by  
31 quartiles.  
32  
33  
34  
35  
36  
37

38 Treatment effect for the primary and continuous secondary outcomes will be assessed through  
39 ANCOVA adjusted for the baseline measurement score. Overall treatment effect over time on all  
40 continuous outcomes, repeatedly collected over the course of the study, will be estimated using  
41 mixed linear models to take into account the correlation within each individual. The mixed linear  
42 model will include random intercept adjusted with the baseline score, time as categorical and the  
43 interaction between treatment and time.  
44  
45  
46  
47  
48  
49  
50  
51

52 Categorical binary efficacy measures will be primarily analyzed using logistic regression. All  
53 tests will be two-sided with P-values less than 0.05 will be considered significant.  
54  
55  
56  
57

**Eligibility criteria:**

Subjects will be recruited from King Fahd University Hospital (an 800 bed teaching hospital located in the Eastern Province of the Kingdom of Saudi Arabia).

Subjects will be included in the study if they fulfil the followings:

- Clinical evidence of musculoskeletal CLBP including subtype classification (nociceptive versus peripheral neuropathic versus central sensitization);
- Age 18-60 years old;
- Primary complaint of pain (at least a score of 5 out of 10 on a 0-10 NRS) in the area between the 12th rib and buttock crease, with or without leg pain for 3 months or more;

Patient will be excluded if they have any of the followings:

- Pregnant or lactating
- Significant spinal pathology (e.g. spinal fracture, cauda equina syndrome, spinal infective or inflammatory diseases, , metastatic);
- Spinal surgery within the preceding 6 months;
- Recent organ transplants.
- Heart pace maker.
- Cardiac arrhythmia, tachycardia conditions or large aneurysm.
- Heavy psychosis.
- Epileptic episodes.

Exit criteria:

Participants will be withdrawn from the study if:

- 1 • Become pregnant;
- 2
- 3
- 4 • Back pain intensify during the trial to a point which need emergency medical
- 5
- 6 intervention;
- 7
- 8
- 9 • Decided to leave the study voluntarily;
- 10
- 11 • Added a new medications (was not taken before) which may affect the patients LBP
- 12
- 13 condition.
- 14
- 15
- 16 • Lack compliance.
- 17
- 18

19 Patients will be instructed to continue any medication they regularly take before the trial,  
20 however, they will be instructed not add any new medications that may affect their back pain  
21 during the trial period. All prescription and over the counter medications taken by the  
22 participants will be recorded.  
23  
24  
25  
26  
27

### 28 **Randomization**

29 Eligible participants will be randomized in a 1:1 ratio to receive either active PLFMF treatment  
30 (experimental arm) or sham treatment (control arm). Randomization list will be centrally  
31 generated, in a stratified fashion, using a random permuted block design of size four and six. The  
32 stratification factor will be subtypes of musculoskeletal CLBP based on pain mechanism  
33 (nociceptive versus peripheral neuropathic versus central sensitization). A researcher who is not  
34 part of the study screening, evaluation or treatment will allocate the participants in one of the  
35 groups using sealed dense, tamperproof and numbered envelopes, prior to recruitment.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Tool:**

50  
51  
52 The BEMER 3000 (BEMER Int. AG) will be pre-programmed to deliver PLFMF (An average of  
53 14  $\mu$ T). The signal comprises of a series of half-wave-shaped sinusoidal intensity variations. The  
54  
55  
56  
57

1 signal which starts with low values slowly increases and then decreases but it does not go back to  
2 the initial value (i.e. stay above zero). The intensity will gradually get denser with the repetition  
3 of the sequence leading to an increase in the ups and downs with repetition. Every second this  
4 procedure will be repeated 33.3 times with a reversal of polarity every 2 minutes.<sup>48</sup>  
5  
6  
7  
8  
9

## 10 11 12 **Blinding**

13  
14 The trial product will be provided in a blinded manner. All the magnetic coils are covered by a  
15 cloth. When switched on the device does not produce any sound or heat to keep patients blinded.  
16  
17 Furthermore, to maintain the blinding of the investigator (and designated staff) an identic  
18 mattress (size) and same colour cloth will be used for all patients independent of treatment group  
19 assignment. Patients and all healthcare providers (therapists and physicians) who care for the  
20 participants during the study will be strictly blinded to randomized interventions. Only the  
21 treating therapist will know what type of treatment the participant will be given. The assessor  
22 and the participants will not have access to such information. The blinding codes will be kept at  
23 the monitoring office of research and research ethics till the end of the trial unless an emergency  
24 developed which requires unbinding. The treating therapist will be asked not to mention or talk  
25 about the treatment groups to others. Upon the completion of the study each participant will be  
26 interviewed to be asked about the group which they think they were at.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 42 **Setting**

43  
44 The trial will be conducted at the department of physical therapy of King Fahd Hospital of the  
45 University. King Fahd Hospital of the University is an 800 beds teaching hospital located at the  
46 Eastern Province of the Kingdom of Saudi Arabia. All researchers are clinicians at the  
47 departments of physical therapy and orthopedics. The trial is scheduled to begin September  
48  
49  
50  
51  
52  
53  
54 2018.  
55  
56  
57

## Procedure

All screening, interventions and evaluation will be done by qualified musculoskeletal physical therapists who have 5 or more years of clinical experience. Potential participants will be asked to participate in the study, if agreed they will be screened for inclusion and exclusion criteria then they will be asked to sign a consent form. Subjects will be classified into peripheral neuropathic, nociceptive or central sensitization musculoskeletal LBP according to Smart et al.<sup>10-12</sup> Each participant will be assigned randomly to either the experimental group which will receive PLFMF and the conventional physical therapy program or the control group which will receive sham PLFMF and the conventional physical therapy program. Patients will be asked to lie down on the magnetic mattress for 20 minutes/session, three sessions a week for a total of 18 sessions (6 weeks). In the treatment group, the BEMER mattress will be activated whereas in the control group (placebo), no magnetic field will be generated. The conventional physical therapy program consists of:

- Hot packs (to cover the lower back area) for 20 minutes;
- Back, hamstring and calf muscles stretching (performed from long sitting position)
- Lumbar erector spinae muscles self-stretching;
- back muscles strengthening (back extension and bridging);
- Abdominal muscles strengthening (posterior pelvic tilt and sit ups);
- Participants will be asked to hold the above positions for 5 seconds. Each exercise will be done 5 times per session with 1 minute rest between any two repetitions.

Each session will last for 60 minutes as follows:

- 20 minutes for active PLFMF or placebo



- 20 minutes for hot packs
- 20 minutes for exercises.

Treating therapist will monitor adherence to the two intervention sessions using a study calendar.

All patients will be evaluated at baseline, end of the 3rd and the 6th week. To assess for effects persistence, participants will be evaluated at 6 weeks, 12 weeks and 24 weeks after completing the 6-week treatment (Figure 1).

Insert Figure 1 about here

## Outcome Measures

1. Numerical rating scale (NRS): Pain severity will be measured by the NRS. It is an 11-point numeric scale with one extreme labeled as no pain (0) and the other extreme worst pain imagined (10). It is a valid and reliable scale.<sup>49</sup> The patient will be asked to indicate the level of his/her pain immediately before the session and 5 minutes after the intervention.

The percentage change in pain will be calculated at each post-baseline assessment as:

$$100 \times \frac{(\text{difference between baseline and post-pain NRS scores})}{\text{baseline NRS score}}$$

2. Short Form 36 (SF-36): An Arabic version of the SF-36 will be used to assess the quality of life of all participants. The validity and reliability of the Arabic versions of the SF-36 was established in a sample of Saudis.<sup>50</sup>

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
3. Disability measurement using the Roland and Morris Disability Questionnaire (RMDQ): is a self-reported, condition-specific questionnaire which consists of 24 questions. It is often used to assess LBP disability. It was translated and adopted into Arabic language.<sup>51</sup>
4. Depression Anxiety Stress Scale 21 (Dass 21): a 21 questions scale which assess the emotional state of depression, anxiety and stress. Each question is assessed in a four points likert scale. The validity and reliability of an Arabic version of the scale has been established.<sup>52</sup>
5. Function measurement will be assessed using Patient Specific Functional Scale (PSFS): it is a valid and reliable measure for physical function in musculoskeletal conditions.<sup>53-54</sup> It measures 3-5 physical activities which are important to the patient and s/he is unable to do without difficulties. Patients rates the difficulty with which they do the function in an 11 points likert scale from 0 (unable to do) to 10 (not at all affected).
6. Global perceived effect (GPE) of condition change: is an one question scale which ask the patient to rate improvement/deterioration numerically from -5= much worse to 5 much better. It is has been recommended as one of the outcomes in clinical trials which study chronic pain.<sup>55</sup> The scale validity and reliability has been established.<sup>56</sup>
7. Pittsburgh Sleep Quality Index (PSQI) is a 19 items questionnaire which assess several aspects of sleep quality (sleep duration, disturbances, quality, efficiency, sleep onset latency, medication, and day-time dysfunction). A global score of sleep quality is the total of the various components of the questionnaire. The higher the score the worse the sleep quality. The questionnaire was translated and validated into Arabic language.<sup>57</sup>
8. Modified Fatigue impact scale (MFIS): is a 21 items questionnaire which was evaluate the fatigue effects on quality of life in patients with chronic diseases. A likert scale from

0 (no effect of fatigue) to 4 (maximum effect of fatigue) is used to score each item of the questionnaire.

### **Safety Measures**

PLFMF has no known side effects, however, long term side effects of PLFMF have not been evaluated. If side effects developed or the symptoms of any participants get worse during the study s/he will be given appropriate medical care till the situation is resolved. Such participants will be withdrawn from the trial, if necessary. Any observed side effects will be recorded and reported to the IRB office at Imam Abdulrahman Bin Faisal University.

### **Privacy and confidentiality**

Screening, assessment and treatment will be done in a private area at King Fahd Hospital of the University in the department of physical therapy. Data will coded, only one of the researchers will have the key for the codes. All data will be saved in a secured computer protected with a password. Only researchers will have access to data. Upon report writing and professional publication data will be presented collectively, none of the participants' identity will be identified.

### **Ethics and dissemination**

The trial was approved by the IRB of the Imam Abdulrahman Bin Faisal University (IRB 2017-03-129). Any amendment to the protocol which may impact on the conduct of the study will be approved by the IRB at Imam Abdulrahman Bin Faisal University before implementation. The trial is also registered with the Australian New Zealand Clinical Trial Registry (Registration Number ACTRN 12618000921280). The trial was registered May 31 2018. While the trial being conducted the monitoring office for research and research ethics at

1 King Fahd Hospital of the University (where the study will be conducted) will monitor the  
2 various milestones of the trial. The study will be explained to all participants by one of the  
3 researchers. All participants will sign a consent form before the beginning of any procedures of  
4 the study.  
5  
6  
7  
8  
9

10 The results of the present trial will be presented in international conferences and will be  
11 published in peer-reviewed journals.  
12  
13

14 **Acknowledgments** We would like to thank the Deanship of Research at Imam Abdulrahman Bin  
15 Faisal University for funding this clinical trial (Grant Number 2017-308-CAMS).  
16  
17

18 **Author contributions** Study concept, design and drafting of the manuscript: FAA and SA.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Funding** This work was supported by Deanship of Research, Imam Abdulrahman Bin Faisal  
University Grant Number 2017-308-CAMS.

**Trial sponsor** Deanship of Research, Imam Abdulrahman Bin Faisal University

Sponsor reference 2017-308-CAMS

Contact name Dr. Naif Almasoud

Address Deanship of research, Imam Abdulrahman Bin Faisal University, West Campus

Telephone 00966133332400

E-mail [dsr@iau.edu.sa](mailto:dsr@iau.edu.sa)

This trial sponsor had no role in the design of this study and will not have any role during its  
execution, analyses, interpretation of the data, or decision to submit results.

**Competing interest** None declared.

**Patient consent** Obtained.

## REFERENCES

1. Balagué F, Mannion AF, Pellisé F, Cedraschi C. Non-specific low back pain. *Lancet* 2012; 379(9814):482-91.
2. Maher C, Underwood M, Buchbinder R (2016). Non-specific low back pain. *Lancet* 2016; 6736(16): 30970-9.
3. Amirdelfan K, McRoberts P, Deer TR. The differential diagnosis of low back pain: a primer on the evolving paradigm. *Neuromodulation* 2014; 17:11-7.
4. Johansson MS, Jensen Stochkendahl M, Hartvigsen J, Boyle E, Cassidy JD. Incidence and prognosis of mid-back pain in the general population: A systematic review. *Eur J Pain* 2017; 21(1):20-8.
5. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study. *Lancet* 2010; 380(9859):2163-96.
6. Saragiotto BT, Maher, CG, Yamato, TP, et al. Motor control exercise for chronic non-specific low-back pain. *Cochrane Database Syst Rev* 2016; 1 CD012004.
7. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J* 2008; 8(1):8-20.
8. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000; 84(1):95-103.
9. Deyo RA, Weinstein JN. Low back pain. *N Engl J Med* 2001; 344:363-70.
10. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 336-44.
11. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 2 of 3: symptoms and signs of peripheral neuropathic pain in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 345-51.
12. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 352-7.
13. Krammer A, Horton S, Tumilty S. Pulsed electromagnetic energy as an adjunct to physiotherapy for the treatment of acute low back pain: a randomised controlled trial. *N Z J Physiother* 2015; 43:16-22
14. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev* 2004; (3):CD001878.
15. Coulter ID, Crawford C, Hurwitz EL, et al. Manipulation and mobilization for treating chronic low back pain: a systemic review and meta-analysis. *Spine J* 2018; 18(5):866-79.
16. Majchrzycki M, Kocur P, Kotwicki T. Deep tissue massage and nonsteroidal anti-inflammatory drugs for low back pain: a prospective randomized trial. *Scientific World J* 2014; doi: 10.1155/2014/287597.

17. Seco JI, Kovacs FM, Urrutia G. The efficacy, safety, effectiveness, and cost-effectiveness of ultrasound and shock wave therapies for low back pain: a systematic review. *Spine J* 2011; 11(10):966-77.
18. Choi HK, Gwon HJ, Kim SR, Park CS, Cho BJ. Effects of active rehabilitation therapy on muscular back strength and subjective pain degree in chronic lower back pain patients. *J Phys Ther Sci* 2016; 28(10):2700-02.
19. Cruz-Díaz D, Romeu M, Velasco-González C, Martínez-Amat A, Hita-Contreras F. The effectiveness of 12 weeks of Pilates intervention on disability, pain and kinesiophobia in patients with chronic low back pain: a randomized controlled trial. *Clin Rehabil* 2018; doi: 10.1177/0269215518768393
20. MacPherson H, Vickers A, Bland M, *et al.* Acupuncture for chronic pain and depression in primary care: a programme of research. Southampton (UK): *NIHR Journals Library* 2017; 5(3) DOI: 10.3310/pgfar05030.
21. Chou R, Turner JA, Devine EB, *et al.* The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med* 2015; 162(4):276-86.
22. Mika JI, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. *Pharmacol Rep* 2013; 65(6):1611-21.
23. Coutinho AD, Gandhi K, Fuldeore RM, Landsman-Blumberg PB, Gandhi S. Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use. *J Opioid Manag* 2018; 14(2):131-41.
24. Daniels CJ, Wakefield PJ, Bub GA, Toombs JD. A Narrative Review of Lumbar Fusion Surgery With Relevance to Chiropractic Practice. *J Chiropr Med* 2016; 15(4): 259-71.
25. Lee J, Shin JS, Lee YJ, *et al.* Long-Term Course of Failed Back Surgery Syndrome (FBSS) Patients Receiving Integrative Korean Medicine Treatment: A 1 Year Prospective Observational Multicenter Study. *PLoS One* 2017; 12(1):e0170972.
26. McLean MJ, Holcomb RR, Wamil AW, Pickett JD, Cavopol AV. Blockade of sensory neuron action potentials by a static magnetic field in the 10 mT range. *Bioelectromagnetics* 1995; 16(1):20-32.
27. Siskin B, Midkiff P, Tweheus T, Markov M. Influence of static magnetic fields on nerve regeneration in vitro. *Environmentalist* 2007; 27(4):477-81.
28. Morris CE, Skalak TC. Acute exposure to a moderate strength static magnetic field reduces edema formation in rats. *Am J Physiol Heart Circ Physiol* 2008; 294(1):H50-7.
29. Weintraub MI, Wolfe GI, Barohn RA, *et al.* Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. *Arch Phys Med Rehabil* 2003; 84(5):736-46.
30. Robertson JA, Théberge J, Weller J, Drost DJ, Prato FS, Thomas AW. Low-frequency pulsed electromagnetic field exposure can alter neuroprocessing in humans. *J R Soc Interface* 2010; 7(44):467-73.
31. Selvam R, Ganesan K, Narayana Raju KV, Gangadharan AC, Manohar BM, Puvanakrishnan R. Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activity. *Life Sci* 2007; 80(26):2403-10.
32. Robertson JA, Juen N, Théberge J, *et al.* Evidence for a dose-dependent effect of pulsed magnetic fields on pain processing. *Neurosci Lett* 2010; 482(2):160-2.

- 1 33. Brook J, Dauphinee DM, Korpinen J, Rawe IM. Pulsed radiofrequency electromagnetic  
2 field therapy: a potential novel treatment of plantar fasciitis. *J Foot Ankle Surg* 2012;  
3 51(3):312-16.
- 4 34. Khoromi S, Blackman MR, Kingman A, *et al.* Low intensity permanent magnets in the  
5 treatment of chronic lumbar radicular pain. *J Pain Symptom Manage* 2007; 34(4):434-45.
- 6 35. Hedén P, Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: a double-  
7 blind randomized pilot study in breast augmentation patients. *Aesthetic Plast Surg* 2008;  
8 32(4): 660-6.
- 9 36. Negm A, Lorbergs A, Macintyre NJ. Efficacy of low frequency pulsed subsensory threshold  
10 electrical stimulation vs placebo on pain and physical function in people with knee  
11 osteoarthritis: systematic review with meta-analysis. *Osteoarthritis Cartilage* 2013;  
12 21(9):1281-9.
- 13 37. Abdulla FA, Abualait T, Alkhamis F, Alsaadi S. Effects of pulsed low frequency  
14 electromagnetic filed on patients with carpel tunnel syndrome. In preparation 2018.
- 15 38. Oke K, Umebese P. Evaluation of the efficacy of pulsed electromagnetic therapy in the  
16 treatment of back pain: a randomized controlled trial in a tertiary hospital in Nigeria. *West*  
17 *Indian Med J* 2013; 62:205-9.
- 18 39. Harden R, Remble T, Houle T, Long J, Markov M, Gallizzi M. Prospective, randomized,  
19 single-blind, sham treatment-controlled study of the safety and efficacy of an  
20 electromagnetic field device for the treatment of chronic low back pain: a pilot study. *Pain*  
21 *Pract* 2007; 7:248-55.
- 22 40. Lee P, Kim Y, Lim Y, *et al.* Efficacy of pulsed electromagnetic therapy for chronic lower  
23 back pain: a randomized, double-blind, placebo-controlled study. *J Int Med Res* 2006;  
24 34:160-7.
- 25 41. Omar AS, Awadalla MA, El-Latif MA. Evaluation of pulsed electromagnetic field therapy  
26 in the management of patients with discogenic lumbar radiculopathy. *Int J Rheum Dis* 2012;  
27 15:e101-8.
- 28 42. Park W-h, Sun S-h, Lee S-g, *et al.* Effect of pulsed electromagnetic field treatment on  
29 alleviation of lumbar myalgia. *J Magn* 2014; 19:161-9.
- 30 43. Andrade R, Duarte H, Pereira R, *et al.* Pulsed electromagnetic field therapy effectiveness in  
31 low back pain: A systematic review of randomized controlled trials. *Porto Biomed J* 2016;  
32 1(5): 156-63.
- 33 44. Nayback-Beebe AM, Yoder LH, Goff BJ, Arzola S, Weidlich C. The effect of pulsed  
34 electromagnetic frequency therapy on health-related quality of life in military service  
35 members with chronic low back pain. *Nurs Outlook*. 2017; 65(5S): S26-S33.
- 36 45. Gyulai F, Rába K, Baranyai I, Berkes E, Bender T. BEMER Therapy Combined with  
37 Physiotherapy in Patients with Musculoskeletal Diseases: A Randomised, Controlled  
38 Double Blind Follow-Up Pilot Study. *Evid Based Complement Alternat Med* 2015; doi:  
39 10.1155/2015/245742.
- 40 46. Hug K, Rösli M. Therapeutic effects of whole-body devices applying pulsed  
41 electromagnetic fields (PEMF): a systematic literature review. *Bioelectromagnetics* 2012;  
42 33(2):95-105.
- 43 47. Chan A-W, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 Statement: Defining standard  
44 protocol items for clinical trials. *Ann Intern Med* 2013; 158(3):200-7.
- 45 48. Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic field therapy on the level of  
46 fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. *J*  
47 *Altern Complement Med* 2009; 15(5):507-11.

1  
2 49. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of

3 **Data category**

**Information**  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. *J*  
29 *Rheumatol* 1990; 17:1022-4.

30 50. Coons SJ, Alabdulmohsin SA, Draugalis JR, Hays RD. Reliability of an Arabic Version of  
31 the RAND-36 Health Survey and its Equivalence to the US-English Version. *Med Care*  
32 1998; 36:428-32.

33 51. Maki DI, Rajab E, Watson PJ, Critchley DJ. Cross-cultural translation, adaptation, and  
34 psychometric testing of the Roland-Morris disability questionnaire into modern standard  
35 Arabic. *Spine (Phila Pa 1976)* 2014; 39(25):E1537-44.

36 52. Ali AM, Ahmed A, Sharaf A, Kawakami N, Abdeldayem SM, Green J. The Arabic Version  
37 of The Depression Anxiety Stress Scale-21: Cumulative scaling and discriminant-validation  
38 testing. *Asian J Psychiatr* 2017; 30:56-8.

39 53. Gross DP, Battié MC, Asante AK. The Patient-Specific Functional Scale: validity in  
40 workers' compensation claimants. *Arch Phys Med Rehabil* 2008; 89(7):1294-99.

41 54. Berghmans D, Lenssen AF, Van Rhijn LW, De Bie RA. The Patient-Specific Functional  
42 Scale: its reliability and responsiveness in patients undergoing a total knee arthroplasty. *J*  
43 *Orthop Sports Phys Ther* 2015; 45(7):550-6.

44 55. Dworkin RH, Turk DC, Farrar JT, *et al*. Core outcome measures for chronic pain clinical  
45 trials: IMMPACT recommendations. *Pain* 2005; 113: 9-19.

46 56. Kamper SJ, Ostelo RWJG, Knol DL, Maher CG, de Vet HCW, Hancock MJ. Global  
47 Perceived Effect scales provided reliable assessments of health transition in people with  
48 musculoskeletal disorders, but ratings are strongly influenced by current status. *J Clin*  
49 *Epidem* 2010; 63:760-66.

50 57. Suleiman KH, Yates BC, Berger AM, Pozehl B, Meza J. Translating the Pittsburgh Sleep  
51 Quality Index into Arabic. *West J Nurs Res* 2010; 32(2):250-68.  
52  
53  
54  
55  
56  
57



1		
2	Primary registry and trial identifying number	Australian New Zealand Clinical Trial Registry
3		ACTRN 12618000921280)
4	Date of registration in primary registry	31/05/2018
5	Secondary identifying numbers	IAU-2017-308-CAMS
6	Source(s) of monetary or material support	King Fahd Hospital of the University
7	Primary sponsor	Imam Abdulrahman Bin Faisal University
8	Secondary sponsor(s)	None
9	Contact for public queries	Fuad A. Abdulla, PhD, PT
10		+966 13 3331308
11		faabdullah@iau.edu.sa
12	Contact for scientific queries	Fuad A. Abdulla, PhD, PT
13		+966 13 3331308
14		faabdullah@iau.edu.sa
15	Public title	Effects of Pulsed Low Frequency Magnetic Field
16		Therapy on Pain Intensity in Patients with
17		Musculoskeletal Chronic Low Back Pain: A
18	Scientific title	Randomized Double Blind Placebo Controlled Trial.
19		Effects of Pulsed Low Frequency Magnetic Field
20		Therapy on Pain Intensity in Patients with
21		Musculoskeletal Chronic Low Back Pain: A
22	Countries of recruitment	Randomized Double Blind Placebo Controlled Trial.
23	Health condition(s) or problem(s) studied	Saudi Arabia
24	Intervention(s)	Chronic Low Back Pain
25		Active comparator: Pulsed low frequency magnetic
26		field (PLFMF, an average of 14 micro tesla for 20
27		minutes) and the conventional physical therapy program
28		(3 times per week for 6 weeks).
29		Placebo comparator: sham PLFMF (the machine will
30		not be activated, i.e. no magnetic field will be
31		generated, for 20 minutes) and the conventional
32		physical therapy program (3 times per week for 6
33		weeks).
34		The conventional physical therapy program consists of:
35		• Hot packs for 20 minutes;
36		• Back, hamstring and calf muscles stretching
37		(performed from long setting position)
38		• Lumbar erector spinae muscles self-stretching;
39		• back muscles strengthening (back extension and
40		bridging);
41		• Abdominal muscles strengthening (posterior
42		pelvic tilt and sit ups);
43		Participants will be asked to hold the above positions
44		for 5 seconds. Each exercise will be done 5 times per
45	Key inclusion and exclusion criteria	session with 1 minute rest between any two repetitions.
46		Ages eligible for study: 18 – 60 years
47		Sexes eligible for study: both
48		Accepts healthy volunteers: no
49		Inclusion Criteria:
50		• Clinical evidence of musculoskeletal chronic low
51		back pain including subtype classification
52		(nociceptive versus peripheral neuropathic versus
53		central sensitization);
54		• Age 18-60 years old;
55		• Primary complaint of pain (at least a score of 5 out
56		of 10 on a 0- 10 numerical rating scale) in the area
57		between the 12th rib and buttock crease, with or
58		
59		
60		

1		without leg pain for 3 months or more;
2		Exclusion Criteria:
3		• Pregnant or lactating
4		• Significant spinal pathology (e.g. spinal fracture, cauda equina syndrome, spinal infective or inflammatory diseases, , metastatic);
5		• Spinal surgery within the preceding 6 months;
6		• Recent organ transplants.
7		• Heart pace maker.
8		• Cardiac arrhythmia, tachycardia conditions or large aneurysm.
9		• Heavy psychosis.
10		• Epileptic episodes.
11	Study type	Interventional
12		Allocation: randomized
13		Allocation concealment: sealed opaque envelopes
14		Sequence generation: Permuted block randomization
15		Intervention model: parallel assignment
16		Masking: double blind (subject, caregiver, investigator, outcomes assessor)
17		Primary purpose: treatment
18	Date of first enrolment	September 2018
19	Target sample size	200
20	Recruitment status	Will begin Recruiting in July
21	Primary outcome(s)	The percentage change in pain intensity by calculating the percentage change in numerical rating scale (NRS) of pain.
22		The percentage change in pain will be calculated at each post-baseline assessment as:
23		$100 \times \frac{(\text{difference between baseline and post-pain NRS scores})}{\text{baseline NRS score}}$
24		All patients will be evaluated at baseline, end of the 3rd and the 6th week from the beginning of intervention. To assess for effects persistence, participants will be also evaluated at 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
25	Key secondary outcomes	a. Quality of life assessed using Short Form 36 (SF-36) quality of life questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
26		b. Disability assessed by the Roland and Morris Disability Questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
27		c. Depression, anxiety and stress assessed by Depression Anxiety Stress Scale 21 questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
28		d. Function measurement assessed by Patient Specific Functional Scale. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52
- the end of the intervention sessions.
- e. Change in condition assessed by Global perceived effect of condition change. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
- f. Quality of sleep assessed by Pittsburgh Sleep Quality Index. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
- g. Fatigue assessed by Modified Fatigue impact scale. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
- 

53 Table 1 Trial Registration Data Set  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Appendix 1

### Consent Form

You are invited to participate in a clinical trial to investigate the long term efficacy and safety of pulsed low frequency magnetic field therapy. The study will be conducted by Prof. Fuad Abdulla, Dr. Saad AlSaadi, Prof. MIR Sadat-Ali, Dr. Fahd AlKhamis, Mr. Hani Alkhawaja and Dr. Serigne Lo (all are affiliated with Imam Abdulrahman Bin Faisal University). The study will be conducted at the department of physical therapy, King Fahd Hospital of the University. Participants in the study will be randomly assigned into two group: group 1 will receive pulsed low frequency magnetic field, hot packs and back exercises while group 2 will receive sham pulsed low frequency magnetic field (i.e. no magnetic field), hot packs and back exercises. Participants are asked to commit one hour three times per week for six weeks for the intervention period then they will be asked to come for evaluation at 6, 12 and 24 weeks after the conclusion of the intervention. At each evaluation time you will asked to rate the pain intensity in your back using an 11 points scale and you will be asked to fill questionnaires to evaluate your quality of life, disability level due to the back pain, psychological status, functional level, effectiveness of intervention received, sleep quality and level of fatigue.

During the intervention period will be asked to lie on a mattress for 20 minutes (which may generate magnetic field or no magnetic field) then hot packs for 20 minutes and back exercises for 20 minutes. You have been selected to participate in this clinical trial because you have chronic low back pain.

Pulsed low frequency magnetic field has no know side effects, however, all participants will be monitored for any type of side effects. If side effects developed or your symptoms get worse during the study you will be given appropriate medical care till the situation is resolved. You may not benefit directly from this research, however, if the pulsed low frequency magnetic field therapy is proven to be effective it will help patients with chronic low back pain. Your participation in this study is on voluntarily basis, you have the right to withdraw from the study at any time without having to provide any reasons for that. Refusal to participate or withdrawal from the study will not affects your rights to the care you are eligible to.

All data collected will be strictly confidential, only researchers involved in this project will have access to your data. All data collected will be coded and analyzed collectively so no participant can be identified when the results are published or presented in conferences.

If you have any questions or concerns please do not hesitate to contact the trial principle investigator Prof. Fuad Abdulla by phone at 13-3331308 or by e-mail [faabdullah@iau.edu.sa](mailto:faabdullah@iau.edu.sa)

1 I, \_\_\_\_\_, voluntarily consent to participate in this clinical trial  
2 as described above. I have had a chance to ask questions of the researcher, and have had any que  
3 stions answered to my satisfaction.  
4  
5  
6  
7  
8  
9  
10


11 \_\_\_\_\_  
12  
13 Participant Signature

11 \_\_\_\_\_  
12  
13 Witness Signature

14  
15  
16  
17  
18 \_\_\_\_\_  
19 Researcher Signature

20  
21  
22  
23  
24 \_\_\_\_\_  
25 Date

**Figure 1.** Flow chart of participation in the 2-arm randomized double blind trial evaluating the efficacy of pulsed low frequency magnetic field therapy (PLFMF) on chronic low back pain (CLBP)



# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	23
Protocol version	#3	Date and version identifier	17
Funding	#4	Sources and types of financial, material, and other support	18
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	18
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	18



1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	18
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	14
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	8
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	9
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	13
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	11
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	13
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	11
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	15
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	12
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	15
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	15
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	9
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	9
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	12
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	12
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	12
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	13
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	13
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	14
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	10
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	10
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	10
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	10
52	analyses		adjusted analyses)	
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	10
56	population and		adherence (eg, as randomised analysis), and any statistical	
57	missing data		methods to handle missing data (eg, multiple imputation)	
58				
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	17
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	13
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	17
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	17
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	17
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	17
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	17
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	18
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

1			and disclosure of contractual agreements that limit such	
2			access for investigators	
3				
4	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	17
5	trial care		compensation to those who suffer harm from trial	
6			participation	
7				
8				
9	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	17
10	trial results		results to participants, healthcare professionals, the public,	
11			and other relevant groups (eg, via publication, reporting in	
12			results databases, or other data sharing arrangements),	
13			including any publication restrictions	
14				
15				
16				
17	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	18
18	authorship		professional writers	
19				
20				
21	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	18
22	reproducible		participant-level dataset, and statistical code	
23	research			
24				
25				
26				
27	Informed consent	#32	Model consent form and other related documentation given	27
28	materials		to participants and authorised surrogates	
29				
30				
31	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	n/a
32			biological specimens for genetic or molecular analysis in the	
33			current trial and for future use in ancillary studies, if	
34			applicable	
35				
36				

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-  
 38 BY-ND 3.0. This checklist was completed on 06. June 2018 using <http://www.goodreports.org/>, a tool  
 39 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## Effects of pulsed low frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomized-double blind placebo-controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024650.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Mar-2019
Complete List of Authors:	Abdulla, Fuad; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Alsaadi, Saad; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Sadat-Ali, MIR; Imam Abdulrahman Bin Faisal University, Department of Orthopedic Surgery Alkhamis, Fahd; Imam Abdulrahman Bin Faisal University, Department of Neurology Alkawaja, Hani; Imam Abdulrahman Bin Faisal University, Department of Physical Therapy Lo, Serigne; Imam Abdulrahman Bin Faisal University, Institute of Research and Medical Consultation; Melanoma Institute Australia
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Complementary medicine, Evidence based practice
Keywords:	Back pain < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT, REHABILITATION MEDICINE, Clinical trials < THERAPEUTICS, Pulsed low frequency magnetic field, Safety

SCHOLARONE™  
Manuscripts

1  
2 **Effects of pulsed low frequency magnetic field therapy on pain intensity in patients with**  
3  
4 **musculoskeletal chronic low back pain: study protocol for a randomized double-blind**  
5  
6 **placebo-controlled trial**  
7

8  
9 Fuad A. Abdulla<sup>1</sup>, Saad AlSaadi<sup>1</sup>, MIR Sadat-Ali<sup>2</sup>, Fahd AlKhamis<sup>3</sup>, Hani Alkhawaja<sup>1</sup>, and Serigne Lo<sup>4,5</sup>.  
10

- 11 1. Department of Physical Therapy, Imam Abdulrahman Bin Faisal University, Dammam, KSA  
12  
13 2. Department of Orthopedic Surgery, Imam Abdulrahman Bin Faisal University, Dammam, KSA  
14  
15 3. Department of Neurology, Imam Abdulrahman Bin Faisal University, Dammam, KSA  
16  
17 4. Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal  
18  
19 University, Dammam, KSA  
20  
21  
22 5. Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia  
23  
24  
25  
26

27 Correspondence to Prof. Fuad A Abdulla:

28  
29 P.O. Box 2435 Dammam 31451, KSA

30  
31 E-mail: faabdullah@iau.edu.sa

32  
33  
34 Tel: 00966133331308  
35  
36

37 Word count: 4363,

38  
39 59 references,

40  
41 One Table,

42  
43 One Figure,

44  
45 Two Appendixes  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** The aim of the present study is to investigate the effectiveness of pulsed low frequency magnetic field (PLFMF) on the management of chronic low back pain (CLBP).

**Methods and Analysis:** A randomized double-blinded controlled clinical trial will be conducted, involving 200 patients with CLBP. Participants will be randomized in a 1:1 ratio to receive either active PLFMF (experimental arm) or sham treatment (control arm) using a permuted-block design which will be stratified according to three subtypes of musculoskeletal CLBP (nociceptive, peripheral neuropathic or central sensitization). The intervention consists of 3 sessions/week for 6 weeks. The primary outcome is the percentage change in Numeric Rating Scale (NRS) pain at week-24 after treatment completion with respect to the baseline. Secondary outcomes include percentage NRS pain during treatment and early after treatment completion, short form 36 quality of life, Roland and Morris Disability Questionnaire; Depression Anxiety Stress Scale 21, Patient Specific Functional Scale, Global perceived effect of condition change, Pittsburgh Sleep Quality Index and Modified Fatigue Impact Scale. Measures will be taken at baseline, 3 and 6 weeks during the intervention and 6, 12 and 24 weeks after completing the intervention. Adverse events between arms will be evaluated. Data will be analyzed on an intention-to-treat basis.

**Ethics and dissemination:** The study is funded by Imam Abdulrahman Bin Faisal University (IAU). It has been approved by the IRB of IAU (IRB- 2017-03-129). The study will be conducted at King Fahd Hospital of the University and will be monitored by the Hospital monitoring office for research and research ethics. The trial is scheduled to begin in September



1  
2 2018. Results obtained will be presented in international conferences and will be published in  
3  
4 peer-reviewed journals.  
5

6  
7 **Trial registration number** ACTRN12618000921280, prospectively.  
8  
9

10 **Keywords:** Low back pain, Pulsed low frequency magnetic field, Randomized double-blinded  
11  
12 controlled clinical trial, Efficacy, Safety  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Strengths and limitations of this study

- The present study is a well-designed trial to investigate the long-term efficacy and safety of pulsed low frequency magnetic field (PLFMF) on the management of musculoskeletal chronic low back pain.
- Subgroup analysis investigating the efficacy of PLFMF on various subtypes of pain based on pain mechanism will be performed. This may help to explain controversial results reported by previous clinical trials.
- Outcome measures include various aspects of low back pain problems (pain intensity as well as disabilities, functional limitations, sleep quality and quality of life).
- All outcome measures used in the present trial are self-report which may potentiate pain and other measured outcomes.

## INTRODUCTION

Chronic low back pain (CLBP) is pain or discomfort localized in the lumbosacral region, with or without leg pain (sciatica) that persists for more than 3 months.<sup>1</sup> Eight out of every 10 adults will experience low back pain (LBP) at least once in their life with more than 60% of such cases have a recurrent LBP.<sup>2</sup> Evidence suggests that LBP has a lifetime prevalence of 40%, and a mean point prevalence of 20%.<sup>3</sup> The causes of LBP are many, they can range from simple spasm or mechanical causes to more serious causes such as herniated disc and different types of cancer.<sup>4</sup> Symptoms of LBP may vary from one patient to another. In many patients the symptoms may go beyond pain to lead to severe consequences such as sleep disturbances, psychological and social problems which may affect the quality of life.<sup>5</sup> CLBP accounts for about 15% of all cases of LBP, however, it has been reported to be the world-leading source of disability.<sup>6</sup> In addition, CLBP is often associated with the socioeconomic burden and psychological distress.<sup>7</sup> There is no published evidence of LBP cost in Saudi Arabia, the treatment cost for LBP in the US is estimated to be more than \$90 billion per year<sup>8</sup> and \$17 billion per year in the UK.<sup>9</sup>

LBP can be classified based on several criteria. It has been classified to acute and chronic based on how long the pain has persisted. It can also be classified into inflammatory and neuropathic based on the underlying mechanism.<sup>10</sup> The main issue is how to differentiate the various subtypes clinically. In many occasions differentiating the various phenotypes clinically is difficult. Smart et al.<sup>11-13</sup> proposed a mechanism-based classification to differentiate between different types of musculoskeletal LBP (central sensitization, peripheral neuropathic and nociceptive).

1 Most of the mechanical low back pain respond to rest and various physical modalities. Different  
2 conservative and surgical interventions have been used to manage CLBP; however, optimal  
3 therapy is still debatable.<sup>14</sup> Many physical therapy interventions were tried in the management of  
4 CLBP such as soft tissue mobilization and neurodynamic techniques,<sup>15 16</sup> massage therapy,<sup>17</sup>  
5 ultrasound, laser therapy, and shock wave therapy,<sup>18</sup> exercises,<sup>19</sup> Pilates practice,<sup>20</sup> and  
6 acupuncture.<sup>21</sup> While some of the rehabilitation interventions were effective in the short term,  
7 none of such interventions produce long term effectiveness in the management of CLBP.<sup>2</sup>

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20 Many pharmacological interventions have been used to manage CLBP. For example, non-steroid  
21 anti-inflammatory drugs and tramadol were mild to moderately effective in reducing pain without  
22 much effects on function.<sup>17</sup> Similarly, opioids, benzodiazepines and duloxetine effects on  
23 reducing CLBP were small without inducing any improvement in function.<sup>22</sup> Other drugs were  
24 used such as Tricyclic antidepressants, gabapentin, however, their efficacy was not established.<sup>23</sup>  
25 Since CLBP persist for long term, pharmacological interventions are not a suitable solution due  
26 to many reasons. Such reasons include toxicity due to long term use, side and adverse effects in  
27 addition to problems with tolerance and addiction.<sup>24</sup> Surgical procedures have been used in some  
28 cases of CLBP with a mixed outcome,<sup>25</sup> however, many patients are reluctant to go through  
29 surgery. Add to that the high cost of the surgery to the health care system. Furthermore, the  
30 number of what is called “failed back surgery syndrome” is in the rise.<sup>26</sup>

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45 Since the conservative approaches currently used to manage CLBP do not seem to be effective  
46 on the long term, new approaches are needed to be developed. The new approaches should be  
47 safe, noninvasive and cost-effective.

48  
49  
50  
51  
52 Several lines of evidence indicate that pulsed low frequency magnetic field (PLFMF) may be an  
53 attractive option for the management of CLBP. Magnetic field blocked the sensory neuron action  
54

1 potential in cultured neurons;<sup>27</sup> however, it enhanced neuronal growth in the presence of growth  
2 factor.<sup>28</sup> In rats, magnetic field suppressed the formation of edema.<sup>29</sup> Weintraub et al.<sup>30</sup> showed  
3 that magnetic field has a pronounced anti-nociceptive effect. Robertson et al.<sup>31</sup> showed that  
4 PLFMF affected pain and thermal signals in normal volunteers. Selvam et al.<sup>32</sup> reported that  
5 PLFMF restored the calcium ATPase activity of the plasma membrane and produced anti-  
6 inflammatory effects. PLFMF also inhibited pain processing in a dose-dependent manner.<sup>33</sup>  
7 Clinically PLFMF has been used for the treatment of different types of pain. Such as plantar  
8 fasciitis,<sup>34</sup> lumbar radicular pain,<sup>35</sup> postoperative pain,<sup>36</sup> peripheral neuropathy,<sup>30</sup> and  
9 osteoarthritis.<sup>37</sup> Recently we concluded a study which showed that PLFMF was effective in  
10 reducing pain, improving sleep and quality of life in patients with carpal tunnel syndrome.<sup>38</sup>  
11 In the case of CLBP, few studies were done and produced conflicting results. While Krammer et  
12 al.,<sup>14</sup> Oke and Umebese,<sup>39</sup> and Harden et al.<sup>40</sup> reported that PLFMF was not superior to sham  
13 treatment in patients with CLBP other studies reported that PLFMF significantly reduced pain  
14 intensity in patients with CLBP.<sup>41-43</sup> Most of the studies which tested the effects of PLFMF on  
15 CLBP suffered from methodological problems and flaws. Such problems included failure to  
16 perform intention to treat as well as lack of proper blindness of patients and researchers. All  
17 these studies failed to classify the CLBP into different subgroups since CLBP is heterogeneous.  
18 Two of the studies reporting positive findings failed to compare PLFMF with other therapeutic  
19 modality.<sup>42 43</sup> All the mentioned studies used small number sample sizes (16 – 40 patients).<sup>44</sup>  
20 Some of these studies did not do any follow-up after the conclusion of the interventions or did a  
21 follow-up for a short period.<sup>45</sup> Finally, the six studies used different machines producing  
22 different magnetic field intensity and frequency and different treatment protocols. Similarly,  
23 various studies reported controversial results regarding the effects of PLFMF on the level of  
24 disability and quality of life in patients with CLBP. Some studies reported that PLFMF improved  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 the level of disability and/or quality of life<sup>41 42 46</sup> while other studies reported no effects for  
2 PLFMF on disability and/or quality of life.<sup>14 43 47</sup> Two systematic reviews investigated the effects  
3  
4 of PLFMF on CLBP. Andrade et al.<sup>45</sup> concluded that PLFMF treatment is superior to placebo  
5  
6 treatment. However, Hug and Roosli<sup>48</sup> concluded that available evidence is not sufficient to  
7  
8 recommend the use of PLFMF clinically. Both reviews recommended better controlled  
9  
10 randomized studies are needed to clarify the effects of PLFMF on CLBP.  
11  
12

13  
14  
15 PLFMF is known to be safe, non-invasive, low cost, easy to administer and has no known side  
16  
17 effects in the management of patients with CLBP.<sup>48</sup> Improving the condition of patients with  
18  
19 CLBP will spare the patient going through several rounds of pharmacological and non-  
20  
21 pharmacological treatment as well as invasive procedures like surgery with the ultimate goal to  
22  
23 improve the patients' quality of life.  
24  
25  
26  
27  
28  
29

## 30 **OBJECTIVES**

31  
32  
33 The primary objective of this randomized controlled trial is to evaluate the long-term efficacy  
34  
35 and safety of PLFMF on the management of CLBP and on increasing the percentage change in  
36  
37 Numeric Rating Scale (NRS) pain at week-24 with respect to baseline score. The percentage  
38  
39 reduction in Numeric Rating Scale (NRS) pain at week-24 will also be evaluated according to  
40  
41 various musculoskeletal CLBP subtypes based on pain mechanism (nociceptive versus peripheral  
42  
43 neuropathic versus central sensitization).<sup>11-13</sup>  
44  
45  
46

47 The secondary objectives are to evaluate the effects of PLFMF on 1) pain intensity during  
48  
49 treatment and early after treatment completion, 2) level of disability, 3) functional levels, 4)  
50  
51 sleep quality, 5) quality of life and 6) fatigue in patients with CLBP. The study will also  
52  
53 investigate the long term side effects of PLFMF.  
54  
55  
56  
57

1 This study will also include subgroups exploratory objectives to clarify the role of PLFMF in the  
2 management of patients diagnosed with different subtypes of musculoskeletal CLBP. To the best  
3 of our knowledge, this trial is the first randomized clinical trial to explore simultaneously the role  
4 of PLFMF in the management of peripheral neuropathic, nociceptive and central sensitization  
5 musculoskeletal LBP patients together.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

## 17 **METHODS AND ANALYSIS**

18  
19  
20 **Study design** This is a two-arm randomized, double-blind, placebo-controlled clinical trial. The  
21 study will be coordinated at the King Fahd Hospital of the University. All participants will be  
22 recruited from the hospital (patients referred to the department, additionally flyers will be  
23 distributed inviting people to participate). This study is funded through the Imam Abdulrahman  
24 Bin Faisal University (grant number 2017-308-CAMS). Ethical approval has been obtained from  
25 the IRB of the Imam Abdulrahman Bin Faisal University (IRB- 2017-03-129). This study is  
26 prospectively registered with the Australian New Zealand Clinical Trials Registry (Registration  
27 Number ACTRN12618000921280). Table 1 shows Trial Registration Data Set. This trial  
28 protocol has been prepared according to the SPIRIT checklist statement (see appendix 1).<sup>49</sup>  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Insert Table 1 about here  
45  
46  
47

### 48 **Sample size and power calculation**

49  
50  
51 Sample size calculation was based on two sample t-tests. We used R function `power.t.test` via R  
52 version 3.4.1 (<https://cran.r-project.org>). A total sample size of 200 (100 in each arm) will achieve  
53 90% power to detect a mean difference of percentage reduction in Numerical rating scale (NRS)  
54  
55  
56  
57

1 pain of 10% between the two treated arms at week-24. The mean percentage reduction in NRS  
2  
3 pain is assumed to be 15% in the control arm (patient treated with SHAM program) and 25% in  
4  
5 patients who receive PLFMF therapy. A 0.2 standard deviation is considered along with a two-  
6  
7 sided significance level (alpha) of 5% using a two-sample equal-variance t-test. The sample size  
8  
9 allows for 15 percent of patients lost to follow-up at week 24. A 10% absolute reduction in  
10  
11 Numerical rating scale (NRS) pain at week-24 will translate into an expected effect size of 0.5.  
12  
13 This means the NRS score of the average person in the active PLFMF arm is 0.5 the standard  
14  
15 deviations above the average person who have had sham treatment, and hence exceed the scores  
16  
17 of 69% of the control group.  
18  
19  
20  
21  
22

23 The 38-item clinical criteria checklist developed by Smart et al.<sup>11-13</sup> will be used to classify patients  
24  
25 into different phenotypes of musculoskeletal CLBP. This method discriminative validity was  
26  
27 established.<sup>11-13</sup> All patients will be analyzed collectively. Subgroup analysis will be performed to  
28  
29 assess the effect of PLFMF on subtypes of pain.  
30  
31  
32  
33  
34  
35  
36

### 37 **Statistical analysis**

38  
39 All randomized patients will be analyzed on the intent-to-treat basis. Safety analyses will be  
40  
41 performed for all patients who received at least one treatment session. Data will be coded and  
42  
43 entered into SPSS program for analysis. Baseline characteristics will be presented by treatment  
44  
45 group. Binary and categorical variables will be summarized by frequencies and percentages.  
46  
47 Percentages will be calculated according to the number of patients for whom data are available.  
48  
49 Where values are missing, the denominator, which will be less than the number of patients  
50  
51 assigned to the treatment group, will be reported either in the body or a footnote of the summary  
52  
53 table. Continuous variables will be summarized by mean and standard deviation as well as by  
54  
55  
56  
57  
58  
59  
60



1  
2 quartiles. Before summarizing continuous outcomes, a test of normality will be performed. If the  
3  
4 outcome is normally distributed, it will be summarized by mean (standard deviation) in each arm  
5  
6 and the difference between arms will be tested using t-test. However, if no evidence of  
7  
8 normality, data will be summarized using the median (interquartile range). In such case, the  
9  
10 Wilcoxon rank sum test will be used to test the difference between arms.  
11

12  
13 Treatment effect for the primary and continuous secondary outcomes will be assessed through  
14  
15 ANCOVA adjusted for the baseline measurement score. Overall treatment effect over time on all  
16  
17 continuous outcomes, repeatedly collected over the course of the study, will be estimated using  
18  
19 mixed linear models to take into account the correlation within each individual. The mixed linear  
20  
21 model will include random intercept adjusted with the baseline score, time as categorical and the  
22  
23 interaction between treatment and time. P-values will not be adjusted for multiplicity. However,  
24  
25 the outcomes are clearly categorized by degree of importance (primary, main secondary and  
26  
27 other secondary) and a limited number of subgroup analyses are pre-specified.  
28  
29

30  
31 Categorical binary efficacy measures will be primarily analyzed using logistic regression. All  
32  
33 tests will be two-sided with P-values less than 0.05 will be considered significant.  
34  
35  
36  
37  
38  
39

#### 40 **Eligibility criteria:**

41  
42  
43 Subjects will be recruited from King Fahd Hospital of the University. Subjects will be included  
44  
45 in the study if they fulfill the followings:  
46  
47

- 48 • Clinical evidence of musculoskeletal CLBP including subtype classification (nociceptive  
49 versus peripheral neuropathic versus central sensitization);  
50  
51
- 52 • Age 18-60 years old;  
53  
54  
55  
56  
57

- 1
- 2
- 3
- 4
- 5
- 6
- Primary complaint of pain (at least a score of 5 out of 10 on a 0-10 NRS) in the area between the 12th rib and buttock crease, with or without leg pain for 3 months or more;

7 Patient will be excluded if they have any of the followings:

8

9

- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- Pregnant or lactating
  - Significant spinal pathology (e.g. spinal fracture, cauda equina syndrome, spinal infective or inflammatory diseases, metastatic);
  - Spinal surgery within the preceding 6 months;
  - Recent organ transplants;
  - Heart pacemaker;
  - Cardiac arrhythmia, tachycardia conditions or large aneurysm;
  - Heavy psychosis;
  - Epileptic episodes.

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Exit criteria:

Participants will be withdrawn from the study if:

- Become pregnant;
- Back pain intensify during the trial to a point which needs emergency medical intervention;
- Decided to leave the study voluntarily;
- Added new medications (was not taken before) which may affect the patients LBP condition.
- Lack of compliance.

1 Patients will be instructed to continue any medication they regularly take before the trial, however,  
2 they will be instructed not to add any new medications that may affect their back pain during the  
3 trial period. All prescription and over the counter medications taken by the participants will be  
4 recorded.  
5  
6  
7  
8  
9

## 10 11 12 13 14 15 **Randomization**

16 Eligible participants will be randomized in a 1:1 ratio to receive either active PLFMF treatment  
17 (experimental arm) or sham treatment (control arm). Randomization list will be centrally  
18 generated, in a stratified fashion, using a random permuted block design of size four and six. The  
19 stratification factor will be subtypes of musculoskeletal CLBP based on pain mechanism  
20 (nociceptive versus peripheral neuropathic versus central sensitization). A researcher who is not  
21 part of the study screening, evaluation or treatment will allocate the participants in one of the  
22 groups using sealed dense, tamperproof and numbered envelopes, prior to recruitment.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Tool:**

40 The BEMER 3000 (BEMER Int. AG) will be pre-programmed to deliver PLFMF (An average of  
41 14  $\mu$ T) a pulse-frequency of 30 Hz and a pulse duration of 30 ms. The signal comprises of a series  
42 of half-wave-shaped sinusoidal intensity variations. The signal which starts with low values slowly  
43 increases and then decreases but it does not go back to the initial value (i.e. stay above zero). The  
44 intensity will gradually get denser with the repetition of the sequence leading to an increase in the  
45 ups and downs with repetition. Every second this procedure will be repeated 33.3 times with a  
46 reversal of polarity every 2 minutes.<sup>50</sup>  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## Blinding

The trial product will be provided in a blinded manner. All the magnetic coils are covered by a cloth. When switched on the device does not produce any sound or heat to keep patients blinded. Furthermore, to maintain blinding of the investigator (and designated staff) an identical mattress (size) and same color cloth will be used for all patients independent of treatment group assignment. Patients and all healthcare providers (therapists and physicians) who care for the participants during the study will be strictly blinded to randomized interventions. Only the treating therapist will know what type of treatment the participant will be given. The assessor and the participants will not have access to such information. The blinding codes will be kept at the monitoring office of research and research ethics till the end of the trial unless an emergency developed which requires unblinding. The treating therapist will be asked not to mention or talk about the treatment groups to others. Upon the completion of the study, each participant will be interviewed to be asked about the group which they think they were at.

## Setting

The trial will be conducted at the department of physical therapy of King Fahd Hospital of the University. King Fahd Hospital of the University is 800 beds teaching hospital located in the Eastern Province of the Kingdom of Saudi Arabia. All researchers are clinicians at the departments of physical therapy and orthopedics. The trial is scheduled to begin in September 2018.

## Procedure

1 All screening, interventions, and evaluation will be done by qualified musculoskeletal physical  
2 therapists who have 5 or more years of clinical experience. Potential participants will be asked to  
3 participate in the study, if agreed they will be screened for inclusion and exclusion criteria then  
4 they will be asked to sign a consent form (see appendix 2). Subjects will be classified to  
5 peripheral neuropathic, nociceptive or central sensitization musculoskeletal LBP according to  
6 criteria established by Smart et al.<sup>11-13</sup> Each participant will be assigned randomly to either the  
7 experimental group which will receive PLFMF and the typical physical therapy program used in  
8 our department or the control group which will receive sham PLFMF and the typical physical  
9 therapy program used in our department. Patients will be asked to lie down on the magnetic  
10 mattress for 20 minutes/session, three sessions a week for a total of 18 sessions (6 weeks). In the  
11 treatment group, the BEMER mattress will be activated whereas, in the control group (placebo),  
12 no magnetic field will be generated. The typical physical therapy program used in our  
13 department consists of:

- 14 • Hot packs (to cover the lower back area) for 20 minutes;
- 15 • Back, hamstring and calf muscles stretching (performed from the long sitting position)
- 16 • Lumbar erector spinae muscles self-stretching;
- 17 • back muscles strengthening (back extension and bridging);
- 18 • Abdominal muscles strengthening (posterior pelvic tilt and sit-ups);
- 19 • Participants will be asked to hold the above positions for 5 seconds. Each exercise will be  
20 done 5 times per session with 1 minute rest between any two repetitions.

21 Each session will last for 60 minutes as follows:

- 22 • 20 minutes for active PLFMF or placebo
- 23 • 20 minutes for hot packs

- 20 minutes for exercises.

Treating therapist will monitor adherence to the intervention sessions using a study calendar.

All patients will be evaluated at baseline, end of the 3rd and the 6th week. To assess for effects persistence, participants will be evaluated at 6 weeks, 12 weeks and 24 weeks after completing the 6-week treatment (Figure 1).

Insert Figure 1 about here

## Outcome Measures

1. Numerical rating scale (NRS): Pain severity will be measured by the NRS. It is an 11-point numeric scale with one extreme labeled as no pain (0) and the other extreme worst pain imagined (10). It is a valid and reliable scale.<sup>51</sup> The patient will be asked to indicate the level of his/her pain immediately before the session and 5 minutes after the intervention.

The percentage change in pain will be calculated at each post-baseline assessment as:

$$100 \times \frac{(\text{difference between baseline and post} - \text{pain NRS scores})}{\text{baseline NRS score}}$$

2. Short Form 36 (SF-36): An Arabic version of the SF-36 will be used to assess the quality of life of all participants. The validity and reliability of the Arabic versions of the SF-36 was established in a sample of Saudis.<sup>52</sup>
3. Disability measurement using the Roland and Morris Disability Questionnaire (RMDQ): is a self-reported, condition-specific questionnaire which consists of 24 questions. It is often used to assess LBP disability. It was translated and adopted into Arabic language.<sup>53</sup>

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
4. Depression Anxiety Stress Scale 21 (Dass 21): a 21 questions scale which assesses the emotional state of depression, anxiety, and stress. Each question is assessed in a four point likert scale. The validity and reliability of an Arabic version of the scale has been established.<sup>54</sup>
5. Function measurement will be assessed using Patient Specific Functional Scale (PSFS): it is a valid and reliable measure for physical function in musculoskeletal conditions.<sup>55 56</sup> It measures 3-5 physical activities which are important to the patient and s/he is unable to do without difficulties. Patients rate the difficulty with which they do the function in an 11 points likert scale from 0 (unable to do) to 10 (not at all affected).
6. Global perceived effect (GPE) of condition change: is a one question scale which asks the patient to rate improvement/deterioration numerically from -5= much worse to 5 much better. It is has been recommended as one of the outcomes in clinical trials which study chronic pain.<sup>57</sup> The scale validity and reliability has been established.<sup>58</sup>
7. Pittsburgh Sleep Quality Index (PSQI) is a 19 items questionnaire which assesses several aspects of sleep quality (sleep duration, disturbances, quality, efficiency, sleep onset latency, medication, and daytime dysfunction). A global score of sleep quality is the total of the various components of the questionnaire. The higher the score the worse the sleep quality. The questionnaire was translated and validated into Arabic language.<sup>59</sup>
8. Modified Fatigue impact scale (MFIS): is a 21 items questionnaire which evaluates the fatigue effects on quality of life in patients with chronic diseases. A likert scale from 0 (no effect of fatigue) to 4 (maximum effect of fatigue) is used to score each item of the questionnaire.

## **Safety measures**

PLFMF has no known side effects, however, long term side effects of PLFMF have not been evaluated. If side effects developed or the symptoms of any participants get worse during the study or the follow-up period s/he will be given appropriate medical care until the situation is resolved. Such participants will be withdrawn from the trial, if necessary. Any observed side effects will be recorded and reported to the IRB office at Imam Abdulrahman Bin Faisal University.

## **Privacy and confidentiality**

Screening, assessment, and treatment will be done in a private area at King Fahd Hospital of the University in the department of physical therapy. Data will be coded, only one of the researchers will have the key for the codes. All data will be saved in a secured computer protected with a password. Only the researchers will have access to data. Upon report writing and professional publication, data will be presented collectively, none of the participants' identity will be identified.

## **Patient and public involvement**

Patients and the public were not involved in the development of this study protocol. However, the obvious lack of satisfactory treatment of chronic low back pain was a major motivator for the study team to develop and conduct this study. The finding of the present study will be disseminated to the participants and the community in general through newsletters and presentations in the community.

## **Ethics and dissemination**



1 The trial was approved by the IRB of Imam Abdulrahman Bin Faisal University (IRB- 2017-03-  
2 129). Any amendment to the protocol which may impact the conduct of the study will be  
3  
4 approved by the IRB at Imam Abdulrahman Bin Faisal University before implementation. The  
5  
6 trial is also registered with the Australian New Zealand Clinical Trial Registry (Registration  
7  
8 Number ACTRN 12618000921280). The trial was registered May 31, 2018. While the trial being  
9  
10 conducted the monitoring office for research and research ethics at King Fahd Hospital of the  
11  
12 University (where the study will be conducted) will monitor the various milestones of the trial.  
13  
14 The study will be explained to all participants by one of the researchers. All participants will sign  
15  
16 a consent form before the beginning of any procedures of the study.  
17  
18 The results of the present trial will be presented in international conferences and will be  
19  
20 published in peer-reviewed journals.  
21  
22  
23  
24  
25  
26  
27  
28

29 **Acknowledgments** We would like to thank the Deanship of Research at Imam Abdulrahman Bin  
30  
31 Faisal University for funding this clinical trial (Grant Number 2017-308-CAMS).  
32  
33  
34  
35

36 **Author contributions** Study concept, design and drafting of the manuscript: FAA and SA.  
37  
38 Critical revision of the manuscript for important intellectual content: MSA, FA, HK. SL  
39  
40 contributed to the statistical design and data analysis. All authors critically read and approved the  
41  
42 final version of the manuscript.  
43  
44  
45  
46

47 **Funding** This work was supported by Deanship of Research, Imam Abdulrahman Bin Faisal  
48  
49 University Grant Number 2017-308-CAMS.  
50  
51  
52  
53

54 **Trial sponsor** Deanship of Research, Imam Abdulrahman Bin Faisal University  
55  
56  
57

1 Sponsor reference 2017-308-CAMS  
2

3  
4 Contact name Dr. Naif Almasoud  
5

6 Address Deanship of research, Imam Abdulrahman Bin Faisal University, West Campus  
7

8 Telephone 00966133332400  
9

10 E-mail [dsr@iau.edu.sa](mailto:dsr@iau.edu.sa)  
11

12  
13 This trial sponsor had no role in the design of this study and will not have any role during its  
14 execution, analyses, interpretation of the data, or decision to submit results.  
15  
16

17  
18  
19  
20 **Competing interest** None declared.  
21

22  
23  
24 **Patient consent** Obtained.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Balagué F, Mannion AF, Pellisé F, Cedraschi C. Non-specific low back pain. *Lancet* 2012; 379(9814):482-91.
2. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet* 2017; 6736(16): 30970-9.
3. Hoy DG, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum* 2012; 64(6):2028-37.
4. Amirdelfan K, McRoberts P, Deer TR. The differential diagnosis of low back pain: a primer on the evolving paradigm. *Neuromodulation* 2014; 17:11-7.
5. Johansson MS, Jensen Stochkendahl M, Hartvigsen J, Boyle E, Cassidy JD. Incidence and prognosis of mid-back pain in the general population: A systematic review. *Eur J Pain* 2017; 21(1):20-8.
6. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study. *Lancet* 2010; 380(9859):2163-96.
7. Saragiotto BT, Maher, CG, Yamato, TP, et al. Motor control exercise for chronic non-specific low-back pain. *Cochrane Database Syst Rev* 2016; 1 CD012004.
8. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J* 2008; 8(1):8-20.
9. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000; 84(1):95-103.
10. Deyo RA, Weinstein JN. Low back pain. *N Engl J Med* 2001; 344:363-70.
11. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 336-44.
12. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 2 of 3: symptoms and signs of peripheral neuropathic pain in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 345-51.
13. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back ( $\pm$  leg) pain. *Man Ther* 2012; 17(4): 352-7.
14. Krammer A, Horton S, Tumilty S. Pulsed electromagnetic energy as an adjunct to physiotherapy for the treatment of acute low back pain: a randomised controlled trial. *N Z J Physiother* 2015; 43:16-22
15. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev* 2004; (3):CD001878.
16. Coulter ID, Crawford C, Hurwitz EL, et al. Manipulation and mobilization for treating chronic low back pain: a systemic review and meta-analysis. *Spine J* 2018; 18(5):866-79.
17. Majchrzycki M, Kocur P, Kotwicki T. Deep tissue massage and nonsteroidal anti-inflammatory drugs for low back pain: a prospective randomized trial. *Scientific World J* 2014; doi: 10.1155/2014/287597.
18. Seco JI, Kovacs FM, Urrutia G. The efficacy, safety, effectiveness, and cost-effectiveness of ultrasound and shock wave therapies for low back pain: a systematic review. *Spine J* 2011; 11(10):966-77.
19. Choi HK, Gwon HJ, Kim SR, Park CS, Cho BJ. Effects of active rehabilitation therapy on muscular back strength and subjective pain degree in chronic lower back pain patients. *J Phys Ther Sci* 2016; 28(10):2700-02.

20. Cruz-Díaz D, Romeu M, Velasco-González C, Martínez-Amat A, Hita-Contreras F. The effectiveness of 12 weeks of Pilates intervention on disability, pain and kinesiophobia in patients with chronic low back pain: a randomized controlled trial. *Clin Rehabil* 2018; doi: 10.1177/0269215518768393
21. MacPherson H, Vickers A, Bland M, *et al.* Acupuncture for chronic pain and depression in primary care: a programme of research. Southampton (UK): *NIHR Journals Library* 2017; 5(3) DOI: 10.3310/pgfar05030.
22. Chou R, Turner JA, Devine EB, *et al.* The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med* 2015; 162(4):276-86.
23. Mika JI, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. *Pharmacol Rep* 2013; 65(6):1611-21.
24. Coutinho AD, Gandhi K, Fuldeore RM, Landsman-Blumberg PB, Gandhi S. Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use. *J Opioid Manag* 2018; 14(2):131-41.
25. Daniels CJ, Wakefield PJ, Bub GA, Toombs JD. A Narrative Review of Lumbar Fusion Surgery With Relevance to Chiropractic Practice. *J Chiropr Med* 2016; 15(4): 259-71.
26. Lee J, Shin JS, Lee YJ, *et al.* Long-Term Course of Failed Back Surgery Syndrome (FBSS) Patients Receiving Integrative Korean Medicine Treatment: A 1 Year Prospective Observational Multicenter Study. *PLoS One* 2017; 12(1):e0170972.
27. McLean MJ, Holcomb RR, Wamil AW, Pickett JD, Cavopol AV. Blockade of sensory neuron action potentials by a static magnetic field in the 10 mT range. *Bioelectromagnetics* 1995; 16(1):20-32.
28. Siskin B, Midkiff P, Tweheus T, Markov M. Influence of static magnetic fields on nerve regeneration in vitro. *Environmentalist* 2007; 27(4):477-81.
29. Morris CE, Skalak TC. Acute exposure to a moderate strength static magnetic field reduces edema formation in rats. *Am J Physiol Heart Circ Physiol* 2008; 294(1):H50-7.
30. Weintraub MI, Wolfe GI, Barohn RA, *et al.* Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. *Arch Phys Med Rehabil* 2003; 84(5):736-46.
31. Robertson JA, Théberge J, Weller J, Drost DJ, Prato FS, Thomas AW. Low-frequency pulsed electromagnetic field exposure can alter neuroprocessing in humans. *J R Soc Interface* 2010; 7(44):467-73.
32. Selvam R, Ganesan K, Narayana Raju KV, Gangadharan AC, Manohar BM, Puvanakrishnan R. Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activity. *Life Sci* 2007; 80(26):2403-10.
33. Robertson JA, Juen N, Théberge J, *et al.* Evidence for a dose-dependent effect of pulsed magnetic fields on pain processing. *Neurosci Lett* 2010; 482(2):160-2.
34. Brook J, Dauphinee DM, Korpinen J, Rawe IM. Pulsed radiofrequency electromagnetic field therapy: a potential novel treatment of plantar fasciitis. *J Foot Ankle Surg* 2012; 51(3):312-16.
35. Khoromi S, Blackman MR, Kingman A, *et al.* Low intensity permanent magnets in the treatment of chronic lumbar radicular pain. *J Pain Symptom Manage* 2007; 34(4):434-45.
36. Hedén P, Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: a double-blind randomized pilot study in breast augmentation patients. *Aesthetic Plast Surg* 2008; 32(4): 660-6.

- 1 37. Negm A, Lorbergs A, Macintyre NJ. Efficacy of low frequency pulsed subsensory threshold  
2 electrical stimulation vs placebo on pain and physical function in people with knee  
3 osteoarthritis: systematic review with meta-analysis. *Osteoarthritis Cartilage* 2013;  
4 21(9):1281-9.
- 5 38. Abdulla FA, Abualait T, Alkhamis F, Alsaadi S. Effects of pulsed low frequency  
6 electromagnetic field on patients with carpal tunnel syndrome. In preparation 2019.
- 7 39. Oke K, Umebese P. Evaluation of the efficacy of pulsed electromagnetic therapy in the  
8 treatment of back pain: a randomized controlled trial in a tertiary hospital in Nigeria. *West*  
9 *Indian Med J* 2013; 62:205-9.
- 10 40. Harden R, Remble T, Houle T, Long J, Markov M, Gallizzi M. Prospective, randomized,  
11 single-blind, sham treatment-controlled study of the safety and efficacy of an  
12 electromagnetic field device for the treatment of chronic low back pain: a pilot study. *Pain*  
13 *Pract* 2007; 7:248-55.
- 14 41. Lee P, Kim Y, Lim Y, et al. Efficacy of pulsed electromagnetic therapy for chronic lower  
15 back pain: a randomized, double-blind, placebo-controlled study. *J Int Med Res* 2006;  
16 34:160-7.
- 17 42. Omar AS, Awadalla MA, El-Latif MA. Evaluation of pulsed electromagnetic field therapy  
18 in the management of patients with discogenic lumbar radiculopathy. *Int J Rheum Dis* 2012;  
19 15:e101-8.
- 20 43. Park W-h, Sun S-h, Lee S-g, et al. Effect of pulsed electromagnetic field treatment on  
21 alleviation of lumbar myalgia. *J Magn* 2014; 19:161-9.
- 22 44. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of  
23 clinical trials registered in clinicaltrials.gov, 2007-2010. *JAMA* 2012; 307(17): 1838-47.
- 24 45. Andrade R, Duarte H, Pereira R, et al. Pulsed electromagnetic field therapy effectiveness in  
25 low back pain: A systematic review of randomized controlled trials. *Porto Biomed J* 2016;  
26 1(5): 156-63.
- 27 46. Nayback-Beebe AM, Yoder LH, Goff BJ, Arzola S, Weidlich C. The effect of pulsed  
28 electromagnetic frequency therapy on health-related quality of life in military service  
29 members with chronic low back pain. *Nurs Outlook*. 2017; 65(5S): S26-S33.
- 30 47. Gyulai F, Rába K, Baranyai I, Berkes E, Bender T. BEMER Therapy Combined with  
31 Physiotherapy in Patients with Musculoskeletal Diseases: A Randomised, Controlled  
32 Double Blind Follow-Up Pilot Study. *Evid Based Complement Alternat Med* 2015; doi:  
33 10.1155/2015/245742.
- 34 48. Hug K, Rössli M. Therapeutic effects of whole-body devices applying pulsed  
35 electromagnetic fields (PEMF): a systematic literature review. *Bioelectromagnetics* 2012;  
36 33(2):95-105.
- 37 49. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining standard  
38 protocol items for clinical trials. *Ann Intern Med* 2013; 158(3):200-7.
- 39 50. Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic field therapy on the level of  
40 fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. *J*  
41 *Altern Complement Med* 2009; 15(5):507-11.
- 42 51. Ferraz MB, Quresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of  
43 pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. *J*  
44 *Rheumatol* 1990; 17:1022-4.
- 45 52. Coons SJ, Alabdulmohsin SA, Draugalis JR, Hays RD. Reliability of an Arabic Version of  
46 the RAND-36 Health Survey and its Equivalence to the US-English Version. *Med Care*  
47 1998; 36:428-32.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
53. Maki D1, Rajab E, Watson PJ, Critchley DJ. Cross-cultural translation, adaptation, and psychometric testing of the Roland-Morris disability questionnaire into modern standard Arabic. *Spine (Phila Pa 1976)* 2014; 39(25):E1537-44.
  54. Ali AM, Ahmed A, Sharaf A, Kawakami N, Abdeldayem SM, Green J. The Arabic Version of The Depression Anxiety Stress Scale-21: Cumulative scaling and discriminant-validation testing. *Asian J Psychiatr* 2017; 30:56-8.
  55. Gross DP, Battié MC, Asante AK. The Patient-Specific Functional Scale: validity in workers' compensation claimants. *Arch Phys Med Rehabil* 2008; 89(7):1294-99.
  56. Berghmans D, Lenssen AF, Van Rhijn LW, De Bie RA. The Patient-Specific Functional Scale: its reliability and responsiveness in patients undergoing a total knee arthroplasty. *J Orthop Sports Phys Ther* 2015; 45(7):550-6.
  57. Dworkin RH, Turk DC, Farrar JT, *et al*. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005; 113: 9-19.
  58. Kamper SJ, Ostelo RWJG, Knol DL, Maher CG, de Vet HCW, Hancock MJ. Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. *J Clin Epidem* 2010; 63:760-66.
  59. Suleiman KH, Yates BC, Berger AM, Pozehl B, Meza J. Translating the Pittsburgh Sleep Quality Index into Arabic. *West J Nurs Res* 2010; 32(2):250-68.

Data category	Information
Primary registry and trial identifying number	Australian New Zealand Clinical Trial Registry ACTRN 12618000921280)
Date of registration in primary registry	31/05/2018
Secondary identifying numbers	IAU-2017-308-CAMS
Source(s) of monetary or material support	King Fahd Hospital of the University
Primary sponsor	Imam Abdulrahman Bin Faisal University
Secondary sponsor(s)	None
Contact for public queries	Fuad A. Abdulla, PhD, PT +966 13 3331308 faabdullah@iau.edu.sa
Contact for scientific queries	Fuad A. Abdulla, PhD, PT +966 13 3331308 faabdullah@iau.edu.sa
Public title	Effects of Pulsed Low Frequency Magnetic Field Therapy on Pain Intensity in Patients with Musculoskeletal Chronic Low Back Pain: A Randomized Double-Blind Placebo Controlled Trial.
Scientific title	Effects of Pulsed Low Frequency Magnetic Field Therapy on Pain Intensity in Patients with Musculoskeletal Chronic Low Back Pain: A Randomized Double-Blind Placebo Controlled Trial.
Countries of recruitment	Saudi Arabia
Health condition(s) or problem(s) studied	Chronic Low Back Pain
Intervention(s)	Active comparator: Pulsed low frequency magnetic field (PLFMF, an average of 14 micro tesla for 20 minutes) and the conventional physical therapy program (3 times per week for 6 weeks). Placebo comparator: sham PLFMF (the machine will not be activated, i.e. no magnetic field will be generated, for 20 minutes) and the conventional physical therapy program (3 times per week for 6 weeks). The conventional physical therapy program consists of:
	<ul style="list-style-type: none"> <li>• Hot packs for 20 minutes;</li> <li>• Back, hamstring and calf muscles stretching (performed from the long sitting position)</li> <li>• Lumbar erector spinae muscles self-stretching;</li> <li>• back muscles strengthening (back extension and bridging);</li> <li>• Abdominal muscles strengthening (posterior pelvic tilt and sit-ups);</li> </ul>
	Participants will be asked to hold the above positions for 5 seconds. Each exercise will be done 5 times per session with 1 minute rest between any two repetitions.
Key inclusion and exclusion criteria	Ages eligible for study: 18 – 60 years Sexes eligible for study: both Accepts healthy volunteers: no Inclusion Criteria:
	<ul style="list-style-type: none"> <li>• Clinical evidence of musculoskeletal chronic low back pain including subtype classification (nociceptive versus peripheral neuropathic versus central sanitization);</li> </ul>

1		<ul style="list-style-type: none"> <li>• Age 18-60 years old;</li> <li>• Primary complaint of pain (at least a score of 5 out of 10 on a 0- 10 numerical rating scale) in the area between the 12th rib and buttock crease, with or without leg pain for 3 months or more;</li> </ul>
2		
3		
4		
5		
6		
7		Exclusion Criteria:
8		<ul style="list-style-type: none"> <li>• Pregnant or lactating</li> <li>• Significant spinal pathology (e.g. spinal fracture, cauda equina syndrome, spinal infective or inflammatory diseases, metastatic);</li> <li>• Spinal surgery within the preceding 6 months;</li> <li>• Recent organ transplants.</li> <li>• Heart pacemaker.</li> <li>• Cardiac arrhythmia, tachycardia conditions or large aneurysm.</li> <li>• Heavy psychosis.</li> <li>• Epileptic episodes.</li> </ul>
9		
10		
11		
12		
13		
14		
15		
16		
17		
18	Study type	Interventional
19		Allocation: randomized
20		Allocation concealment: sealed opaque envelopes
21		Sequence generation: Permuted block randomization
22		Intervention model: parallel assignment
23		Masking: double-blind (subject, caregiver, investigator, outcomes assessor)
24		Primary purpose: treatment
25		September 2018
26	Date of first enrolment	September 2018
27	Target sample size	200
28	Recruitment status	Will begin Recruiting in July
29	Primary outcome(s)	The percentage change in pain intensity by calculating the percentage change in numerical rating scale (NRS) of pain.
30		The percentage change in pain will be calculated at each post-baseline assessment as:
31		$100 \times \frac{(\text{difference between baseline and post - pain NRS scores})}{\text{baseline NRS score}}$
32		All patients will be evaluated at baseline, end of the 3rd and the 6th week from the beginning of the intervention. To assess for effects persistence, participants will be also evaluated at 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
33		
34		
35		
36		
37		
38		
39		
40		
41	Key secondary outcomes	a. Quality of life assessed using Short Form 36 (SF-36) quality of life questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
42		b. Disability assessed by the Roland and Morris Disability Questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
43		c. Depression, anxiety, and stress assessed by Depression Anxiety Stress Scale 21 questionnaire. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20
- d. Function measurement assessed by the Patient Specific Functional Scale. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
  - e. Change in condition assessed by Global perceived effect of condition change. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
  - f. Quality of sleep assessed by the Pittsburgh Sleep Quality Index. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
  - g. Fatigue assessed by Modified Fatigue impact scale. Time points: baseline, end of the 3rd and the 6th week from the beginning of the intervention. 6 weeks, 12 weeks and 24 weeks after the end of the intervention sessions.
- 

21 Table 1 Trial Registration Data Set  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart of participation in the 2-arm randomized double-blind trial evaluating the efficacy of pulsed low frequency magnetic field therapy (PLFMF) on chronic low back pain (CLBP)

105x105mm (300 x 300 DPI)

# Appendix 1

## Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

### Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	23
Protocol version	#3	Date and version identifier	17
Funding	#4	Sources and types of financial, material, and other support	18
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	18

1	Roles and	#5b	Name and contact information for the trial sponsor	18
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	18
9	responsibilities:		collection, management, analysis, and interpretation of	
10	sponsor and funder		data; writing of the report; and the decision to submit the	
11			report for publication, including whether they will have	
12			ultimate authority over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
17	responsibilities:		centre, steering committee, endpoint adjudication	
18	committees		committee, data management team, and other individuals	
19			or groups overseeing the trial, if applicable (see Item 21a	
20			for data monitoring committee)	
21				
22				
23				
24	Background and	#6a	Description of research question and justification for	5
25	rationale		undertaking the trial, including summary of relevant	
26			studies (published and unpublished) examining benefits	
27			and harms for each intervention	
28				
29				
30				
31	Background and	#6b	Explanation for choice of comparators	14
32	rationale: choice of			
33	comparators			
34				
35				
36	Objectives	#7	Specific objectives or hypotheses	8
37				
38				
39	Trial design	#8	Description of trial design including type of trial (eg,	9
40			parallel group, crossover, factorial, single group),	
41			allocation ratio, and framework (eg, superiority,	
42			equivalence, non-inferiority, exploratory)	
43				
44				
45				
46	Study setting	#9	Description of study settings (eg, community clinic,	13
47			academic hospital) and list of countries where data will be	
48			collected. Reference to where list of study sites can be	
49			obtained	
50				
51				
52	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	11
53			applicable, eligibility criteria for study centres and	
54			individuals who will perform the interventions (eg,	
55			surgeons, psychotherapists)	
56				
57				
58				
59				
60				

1	Interventions:	#11a	Interventions for each group with sufficient detail to allow	13
2	description		replication, including how and when they will be	
3			administered	
4				
5				
6	Interventions:	#11b	Criteria for discontinuing or modifying allocated	11
7	modifications		interventions for a given trial participant (eg, drug dose	
8			change in response to harms, participant request, or	
9			improving / worsening disease)	
10				
11				
12				
13	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	15
14	adherence		and any procedures for monitoring adherence (eg, drug	
15			tablet return; laboratory tests)	
16				
17				
18	Interventions:	#11d	Relevant concomitant care and interventions that are	12
19	concomitant care		permitted or prohibited during the trial	
20				
21				
22	Outcomes	#12	Primary, secondary, and other outcomes, including the	15
23			specific measurement variable (eg, systolic blood	
24			pressure), analysis metric (eg, change from baseline, final	
25			value, time to event), method of aggregation (eg, median,	
26			proportion), and time point for each outcome. Explanation	
27			of the clinical relevance of chosen efficacy and harm	
28			outcomes is strongly recommended	
29				
30				
31				
32				
33	Participant timeline	#13	Time schedule of enrolment, interventions (including any	15
34			run-ins and washouts), assessments, and visits for	
35			participants. A schematic diagram is highly recommended	
36			(see Figure)	
37				
38				
39				
40	Sample size	#14	Estimated number of participants needed to achieve study	9
41			objectives and how it was determined, including clinical	
42			and statistical assumptions supporting any sample size	
43			calculations	
44				
45				
46				
47	Recruitment	#15	Strategies for achieving adequate participant enrolment to	9
48			reach target sample size	
49				
50				
51	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	12
52	generation		computer-generated random numbers), and list of any	
53			factors for stratification. To reduce predictability of a	
54			random sequence, details of any planned restriction (eg,	
55			blocking) should be provided in a separate document that	
56				
57				
58				
59				
60				

is unavailable to those who enrol participants or assign interventions

1			
2			
3			
4	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,
5	concealment		central telephone; sequentially numbered, opaque, sealed
6	mechanism		envelopes), describing any steps to conceal the sequence
7			until interventions are assigned
8			
9			
10			
11	Allocation:	#16c	Who will generate the allocation sequence, who will enrol
12	implementation		participants, and who will assign participants to
13			interventions
14			
15			
16	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,
17			trial participants, care providers, outcome assessors, data
18			analysts), and how
19			
20			
21	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is
22	emergency		permissible, and procedure for revealing a participant's
23	unblinding		allocated intervention during the trial
24			
25			
26			
27	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,
28			and other trial data, including any related processes to
29			promote data quality (eg, duplicate measurements,
30			training of assessors) and a description of study
31			instruments (eg, questionnaires, laboratory tests) along
32			with their reliability and validity, if known. Reference to
33			where data collection forms can be found, if not in the
34			protocol
35			
36			
37			
38			
39	Data collection plan:	#18b	Plans to promote participant retention and complete
40	retention		follow-up, including list of any outcome data to be
41			collected for participants who discontinue or deviate from
42			intervention protocols
43			
44			
45			
46	Data management	#19	Plans for data entry, coding, security, and storage,
47			including any related processes to promote data quality
48			(eg, double data entry; range checks for data values).
49			Reference to where details of data management
50			procedures can be found, if not in the protocol
51			
52			
53			
54	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary
55			outcomes. Reference to where other details of the
56			statistical analysis plan can be found, if not in the protocol
57			
58			
59			
60			

1	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	10
2	analyses		adjusted analyses)	
3				
4	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	10
5	population and		adherence (eg, as randomised analysis), and any	
6	missing data		statistical methods to handle missing data (eg, multiple	
7			imputation)	
8				
9				
10				
11	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	17
12	formal committee		summary of its role and reporting structure; statement of	
13			whether it is independent from the sponsor and competing	
14			interests; and reference to where further details about its	
15			charter can be found, if not in the protocol. Alternatively,	
16			an explanation of why a DMC is not needed	
17				
18				
19				
20				
21	Data monitoring:	#21b	Description of any interim analyses and stopping	13
22	interim analysis		guidelines, including who will have access to these interim	
23			results and make the final decision to terminate the trial	
24				
25				
26				
27	Harms	#22	Plans for collecting, assessing, reporting, and managing	17
28			solicited and spontaneously reported adverse events and	
29			other unintended effects of trial interventions or trial	
30			conduct	
31				
32				
33	Auditing	#23	Frequency and procedures for auditing trial conduct, if	17
34			any, and whether the process will be independent from	
35			investigators and the sponsor	
36				
37				
38				
39	Research ethics	#24	Plans for seeking research ethics committee / institutional	17
40	approval		review board (REC / IRB) approval	
41				
42				
43	Protocol	#25	Plans for communicating important protocol modifications	17
44	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
45			relevant parties (eg, investigators, REC / IRBs, trial	
46			participants, trial registries, journals, regulators)	
47				
48				
49	Consent or assent	#26a	Who will obtain informed consent or assent from potential	17
50			trial participants or authorised surrogates, and how (see	
51			Item 32)	
52				
53				
54				
55	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
56	ancillary studies		participant data and biological specimens in ancillary	
57			studies, if applicable	
58				
59				
60				

1	Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	17
2				
3				
4				
5				
6				
7				
8	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	18
9				
10				
11	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17
12				
13				
14				
15				
16				
17	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	17
18				
19				
20				
21				
22	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
23				
24				
25				
26				
27				
28				
29				
30	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	18
31				
32				
33				
34	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	18
35				
36				
37				
38				
39				
40	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	27
41				
42				
43				
44	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
45				
46				
47				
48				
49				

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 06. June 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)



## Appendix 2

### Consent Form

You are invited to participate in a clinical trial to investigate the long term efficacy and safety of pulsed low frequency magnetic field therapy. The study will be conducted by Prof. Fuad Abdulla, Dr. Saad AlSaadi, Prof. MIR Sadat-Ali, Dr. Fahd AlKhamis, Mr. Hani Alkhawaja and Dr. Serigne Lo (all are affiliated with Imam Abdulrahman Bin Faisal University). The study will be conducted at the department of physical therapy, King Fahd Hospital of the University. Participants in the study will be randomly assigned into two groups: group 1 will receive pulsed low frequency magnetic field, hot packs and back exercises while group 2 will receive sham pulsed low frequency magnetic field (i.e. no magnetic field), hot packs and back exercises. Participants are asked to commit one hour three times per week for six weeks (the intervention period) then they will be asked to come for evaluation at 6, 12 and 24 weeks after the conclusion of the intervention. At each evaluation time you will be asked to rate the pain intensity in your back using an 11 points scale and you will be asked to fill questionnaires to evaluate your quality of life, disability level due to the back pain, psychological status, functional level, effectiveness of intervention received, sleep quality and level of fatigue.

During the intervention period will be asked to lie on a mattress for 20 minutes (which may generate a magnetic field or no magnetic field) then hot packs for 20 minutes and back exercises for 20 minutes. You have been selected to participate in this clinical trial because you have chronic low back pain.

Pulsed low frequency magnetic field has no known side effects, however, all participants will be monitored for any type of side effects. If side effects develop or your symptoms get worse during the study you will be given appropriate medical care till the situation is resolved. You may not benefit directly from this research, however, if the pulsed low frequency magnetic field therapy is proven to be effective it will help patients with chronic low back pain. Your participation in this study is on a voluntary basis, you have the right to withdraw from the study at any time without having to provide any reasons for that. Refusal to participate or withdrawal from the study will not affect your rights to the care you are eligible to.

All data collected will be strictly confidential, only researchers involved in this project will have access to your data. All data collected will be coded and analyzed collectively so no participant can be identified when the results are published or presented in conferences. The study is funded by deanship of research at Imam Abdulrahman Bin Faisal University.

If you have any questions or concerns please do not hesitate to contact the trial principal investigator Prof. Fuad Abdulla by phone at 13-3331308 or by e-mail faabdullah@iau.edu.sa

1  
2 I, \_\_\_\_\_, voluntarily consent to participate in this clinical trial  
3 as described above. I have had a chance to ask questions of the researchers, and have had any qu  
4 estions answered to my satisfaction.  
5  
6  
7  
8  
9  
10

11 \_\_\_\_\_  
12  
13 Participant Signature

\_\_\_\_\_

Witness Signature

14  
15  
16  
17  
18 \_\_\_\_\_  
19 Researcher Signature

20  
21  
22  
23  
24 \_\_\_\_\_  
25 Date  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60